AU2013200590B2 - Compositions and methods for making and using nanoemulsions - Google Patents
Compositions and methods for making and using nanoemulsions Download PDFInfo
- Publication number
- AU2013200590B2 AU2013200590B2 AU2013200590A AU2013200590A AU2013200590B2 AU 2013200590 B2 AU2013200590 B2 AU 2013200590B2 AU 2013200590 A AU2013200590 A AU 2013200590A AU 2013200590 A AU2013200590 A AU 2013200590A AU 2013200590 B2 AU2013200590 B2 AU 2013200590B2
- Authority
- AU
- Australia
- Prior art keywords
- nanoemulsion
- microfluidized
- population
- particles
- uniform
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 337
- 238000000034 method Methods 0.000 title claims abstract description 112
- 239000000203 mixture Substances 0.000 title abstract description 114
- 239000002245 particle Substances 0.000 claims abstract description 192
- 150000001875 compounds Chemical class 0.000 claims abstract description 75
- 235000021436 nutraceutical agent Nutrition 0.000 claims abstract description 42
- 239000002612 dispersion medium Substances 0.000 claims abstract description 34
- 239000002105 nanoparticle Substances 0.000 claims abstract description 24
- 235000002378 plant sterols Nutrition 0.000 claims description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- 239000007788 liquid Substances 0.000 claims description 41
- 238000009826 distribution Methods 0.000 claims description 39
- 239000003921 oil Substances 0.000 claims description 33
- 235000019198 oils Nutrition 0.000 claims description 33
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 29
- 229920000136 polysorbate Polymers 0.000 claims description 28
- 239000002537 cosmetic Substances 0.000 claims description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 21
- -1 fatty acid monoglycerides Chemical class 0.000 claims description 21
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 20
- 239000000194 fatty acid Substances 0.000 claims description 20
- 229930195729 fatty acid Natural products 0.000 claims description 20
- 229930003799 tocopherol Natural products 0.000 claims description 20
- 239000011732 tocopherol Substances 0.000 claims description 20
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 19
- 235000010445 lecithin Nutrition 0.000 claims description 19
- 229940067606 lecithin Drugs 0.000 claims description 19
- 239000000787 lecithin Substances 0.000 claims description 19
- 235000010384 tocopherol Nutrition 0.000 claims description 19
- 229960001295 tocopherol Drugs 0.000 claims description 19
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 19
- 235000012680 lutein Nutrition 0.000 claims description 18
- 239000001656 lutein Substances 0.000 claims description 18
- 229960005375 lutein Drugs 0.000 claims description 18
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 18
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 18
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 18
- 239000003995 emulsifying agent Substances 0.000 claims description 16
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- 108010073771 Soybean Proteins Proteins 0.000 claims description 12
- 235000012716 cod liver oil Nutrition 0.000 claims description 12
- 239000003026 cod liver oil Substances 0.000 claims description 12
- 229940001941 soy protein Drugs 0.000 claims description 12
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims description 11
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims description 11
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims description 11
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 235000010930 zeaxanthin Nutrition 0.000 claims description 11
- 239000001775 zeaxanthin Substances 0.000 claims description 11
- 229940043269 zeaxanthin Drugs 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 9
- 239000012736 aqueous medium Substances 0.000 claims description 8
- 229940068965 polysorbates Drugs 0.000 claims description 8
- 239000006185 dispersion Substances 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 229920002545 silicone oil Polymers 0.000 claims description 4
- 235000013311 vegetables Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 abstract description 43
- 230000008569 process Effects 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 18
- 238000003801 milling Methods 0.000 abstract description 12
- 230000001580 bacterial effect Effects 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 238000000227 grinding Methods 0.000 abstract description 10
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 77
- 238000003756 stirring Methods 0.000 description 35
- 238000009472 formulation Methods 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 29
- 235000012000 cholesterol Nutrition 0.000 description 26
- 235000021323 fish oil Nutrition 0.000 description 23
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 22
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 22
- 235000005911 diet Nutrition 0.000 description 22
- 235000012661 lycopene Nutrition 0.000 description 22
- 239000001751 lycopene Substances 0.000 description 22
- 229960004999 lycopene Drugs 0.000 description 22
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 22
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 22
- 230000037213 diet Effects 0.000 description 20
- 235000013336 milk Nutrition 0.000 description 19
- 239000008267 milk Substances 0.000 description 19
- 210000004080 milk Anatomy 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 13
- 230000000260 hypercholesteremic effect Effects 0.000 description 13
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 13
- 229920000053 polysorbate 80 Polymers 0.000 description 13
- 235000012424 soybean oil Nutrition 0.000 description 13
- 239000003549 soybean oil Substances 0.000 description 13
- 229930182558 Sterol Natural products 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000000693 micelle Substances 0.000 description 12
- 150000003432 sterols Chemical class 0.000 description 12
- 235000003702 sterols Nutrition 0.000 description 12
- 239000003963 antioxidant agent Substances 0.000 description 11
- 235000006708 antioxidants Nutrition 0.000 description 11
- 235000021466 carotenoid Nutrition 0.000 description 11
- 150000001747 carotenoids Chemical class 0.000 description 11
- 235000015205 orange juice Nutrition 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 10
- 230000001590 oxidative effect Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000004530 micro-emulsion Substances 0.000 description 9
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 9
- 229940068968 polysorbate 80 Drugs 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000008367 deionised water Substances 0.000 description 8
- 235000015872 dietary supplement Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 241000699800 Cricetinae Species 0.000 description 7
- 241000699694 Gerbillinae Species 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 6
- 238000000265 homogenisation Methods 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000008347 soybean phospholipid Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 235000021119 whey protein Nutrition 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 4
- 230000001906 cholesterol absorption Effects 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000008297 liquid dosage form Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 4
- 229950005143 sitosterol Drugs 0.000 description 4
- 235000000891 standard diet Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 3
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 3
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 3
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 3
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000004426 flaxseed Nutrition 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 210000005095 gastrointestinal system Anatomy 0.000 description 3
- 235000019674 grape juice Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 3
- 229940025508 lutein / zeaxanthin Drugs 0.000 description 3
- 235000013310 margarine Nutrition 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 235000015500 sitosterol Nutrition 0.000 description 3
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 229960004394 topiramate Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- VGSSUFQMXBFFTM-UHFFFAOYSA-N (24R)-24-ethyl-5alpha-cholestane-3beta,5,6beta-triol Natural products C1C(O)C2(O)CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 VGSSUFQMXBFFTM-UHFFFAOYSA-N 0.000 description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 150000001841 cholesterols Chemical class 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960001929 meloxicam Drugs 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- 229940068778 tocotrienols Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101500002116 Agrotis ipsilon Tachykinin-related peptide 6 Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 240000003890 Commiphora wightii Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012424 Freeze-thaw process Methods 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000207836 Olea <angiosperm> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- 239000011774 beta-cryptoxanthin Substances 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical class O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000003181 co-melting Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940114123 ferulate Drugs 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 1
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- CNOIXMULOQWVGR-IKYXTRRCSA-N halocyanthiaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)CC12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C#CC3=C(C)CC(O)CC3(C)C CNOIXMULOQWVGR-IKYXTRRCSA-N 0.000 description 1
- CNOIXMULOQWVGR-ABUIXNMTSA-N halocynthiaxanthin Chemical compound C([C@]12[C@@](O1)(C)C[C@@H](O)CC2(C)C)C(=O)C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C#CC1=C(C)C[C@@H](O)CC1(C)C CNOIXMULOQWVGR-ABUIXNMTSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000011346 highly viscous material Substances 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 229940080553 normosol-m Drugs 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000009268 pathologic speech processing Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
C:\NRPorlbl\DCC\SCG\4907465_ .DOC-5102/2013 Abstract The present invention discloses an improved nanoemulsion comprising a uniform and discrete range of very small particle nano-sized diameters. This uniformity results in improved 5 bioavailability of incorporated compounds (i.e., pharmaceuticals or nutraceuticals) as reflected in various pharmacokinetic parameters including, but not limited to, decreased Tmax, increased Cmax, and increased AUC. The improved method of making these uniform nanoemulsions utilizes microfluidization which differs in both process and mechanics when compared to conventional milling and grinding techniques used to generate nanoparticulate 10 compositions. Further, the improvement results, in part, from a novel step of mixing a substantially soluble compound into a heated dispersion medium. This is unlike current nanoparticulate composition methods that mix an insoluble compound with an unheated dispersion medium. Further, these nanoemulsions are observed to be bacterial-resistant and stable to extremes in both temperature and pH changes. Consequently, these nanoemulsions 15 are expected to have a significantly prolonged shelf-life than currently available nanoemulsions.
Description
C:\NRPortbl\DCC\SCGW907465_ l.DOC-5/02/2013 2013200590 05 Feb 2013
Compositions and Methods for Making and Using Nanoemulsions
This is a divisional of Australian Patent Application No. 2006346369, the entire contents of which are incorporated herein by reference. 5
Field of Invention
The present invention relates to the field of nanoemulsions. In one embodiment, nanoemulsions are made using high shear stress technology. In one embodiment, the invention comprises uniform microfluidized nanoemulsions. In another embodiment, the uniform 10 nanoemulsion comprises a compound such as a pharmaceutical, nutraceutical, or cosmeceutical. In one embodiment, the uniform nanoemulsion comprises improved pharmacokinetic parameters when compared to conventional nanoparticulate compositions and/or nanoemulsions. In one embodiment, the present invention contemplates a method of making a bacteria-resistant nanoemulsion. 15
Background of the Invention
Micro/nanoemulsion technology has substantial commercial value. In relation to the nutraceutical area alone, the market value is estimated as a 250 billion dollar business worldwide. Consequently, the ability to incorporate lipid soluble nutraceuticals into beverages (the 20 fastest-growing component of the food industry) as well as low or no fat foods is of important interest.
What is needed is a nanoemulsion that: i) has improved temperature and pH stability; ii) improved bioavailability; and iii) improved shelf-life due to microbial resistance. In addition, nanoemulsions should be relatively easy and inexpensive to prepare. 25
Summary
The present invention relates to the field of nanoemulsions. In one embodiment, the nanoemulsion is made using a high shear stress technology. In one embodiment, the invention comprises uniform microfluidized nanoemulsions. In another embodiment, the uniform 30 nanoemulsion comprises a compound such as a pharmaceutical, nutraceutical, or cosmeceutical. In one embodiment, the uniform nanoemulsion comprises improved pharmacokinetic parameters when compared to conventional nanoparticulate 1 H:\sxdUnterwoven\NRPortbl\DCC\SXD\l 1758881.1 .docx.-13/10/2016 2013200590 13 Oct 2016 compositions and/or nanoemulsions. In one embodiment, the present invention contemplates a method of making a bacteria-resistant nanoemulsion.
In one embodiment, the present invention provides a method, comprising: a) providing; 5 i) a premix comprising a liquid dispersion medium selected from oil-based media and aqueous media; an emulsifier selected from fatty acid monoglycerides, fatty acid diglycerides, and polysorbates; and 10 a compound that is substantially soluble in the liquid dispersion medium; and ii) a device capable of creating a continuous turbulent flow under high pressure; b) using said device to create a uniform nanoemulsion comprising a population 15 of nanoparticles, wherein, when the premix is subjected to single-pass microfluidization, the uniform nanoemulsion is generated, the nanoemulsion being uniform in that: less than 3% of the nanoparticles show a diameter distribution outside a specified range, the specified range being that the difference between the minimum diameter and 20 maximum diameter does not exceed 600 nm; and the nanoparticles in the population have diameters wherein the specified range is between approximately 10 nm and 100 nm.
In one embodiment, the present invention contemplates a nanoemulsion comprising a population of particles having maximum and minimum diameters, wherein the difference 25 between said maximum and minimum diameters does not exceed 100 nm.
In one embodiment, the present invention contemplates a nanoemulsion comprising a population of particles having diameters between approximately 10 and approximately 110 nanometers, wherein said nanoemulsion is not contaminated by particles having diameters larger than 110 nanometers. In one embodiment, the particles encapsulate a 30 compound. In one embodiment, the compound is a pharmaceutical. In another embodiment, the compound is a nutraceutical. 2 H:\sxd\Interwoven\NRPortbl\DCC\SXD\l 1622132_1 .docx-7/10/2016 2013200590 07 Oct 2016
In one embodiment, the present invention contemplates a nanoemulsion comprising a first and second population of particles, wherein the majority of particles in said first population have diameters between approximately 10 and approximately 20 nanometers, wherein the majority of particles in said second population have diameters between 5 approximately 40 and approximately 80 nanometers, wherein said nanoemulsion is uncontaminated by particles having diameters larger than 110 nanometers. In one embodiment, the particles encapsulate a compound. In one embodiment, the compound is a pharmaceutical. In one embodiment, the compound is a nutraceutical. A nanoemulsion comprising a population of particles having diameters between 10 approximately 50 and approximately 150 nanometers, wherein said nanoemulsion is not contaminated by particles having diameters larger than 160 nanometers. In one embodiment, the particles encapsulate a compound. In one embodiment, the compound is a pharmaceutical. In one embodiment, the compound is a nutraceutical.
In one embodiment, the present invention contemplates a method, comprising: 15 a) providing; i) a premix comprising a compound and a liquid dispersion medium, wherein said compound has a solubility greater than 30 mg/ml in said medium; and ii) a microfluidizer capable of maintaining at least 25,000 PSI; b) using a single pass exposure of said premix to said microfluidizer to create a population of nanoemulsion particles having diameters ranging approximately between 10 - 110 nm. In one embodiment, the 20 dispersion medium is selected from the group consisting of aqueous media and oil-based
2A WO 2008/010788 2013200590 05 Feb 2013 PCT/US2006/026918 media. In one embodiment, the aqueous media is selected trom the group consisting of water, ringers solution, dextrose, and short chain alcohols. In one embodiment, the oil-based media is selected from the group including, but not limited to, saturated and unsaturated oils from vegetable and marine sources, silicone oils, mineral oils, and plant-5 derived oils. In one embodiment, the compound is selected from the group including, but not limited to, a plant sterol, cod liver oil, tocopherol, lecithin, lutein, zeaxanthin, and soy protein.
In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a heated dispersion medium; ii) a compound having substantial solubility in 10 said medium; and iii) a microfluidizer capable of making a uniform nanoemulsion from said medium; b) adding said compound to said medium at a temperature of at least 70°C to create a premix; and c) microfluidizing said premix at a pressure of at least 25,000 PSI to create said nanoemulsion having particle diameters ranging between 10-110 nm. In one embodiment, said dispersion medium is selected from the group consisting of 15 soybean oil and water. In one embodiment, said dispersion medium is heated to at least 65°C. In one embodiment, said compound may be selected from the group comprising a plant sterol, cod liver oil, tocopherol, lecithin, lutein, zeaxanthin, lycopene, whey protein, and soy protein. In one embodiment, the nanoemulsion encapsulates the compound. In one embodiment, 86% of said particle diameters have a 54 nm average diameter. In one 20 embodiment, 14% of said particles diameters have a 16 nm average diameter, hi one embodiment, 82% of said particle diameters have a 64 nm average diameter. In one embodiment, 17% of said particle diameters have a 19 nm average diameter. In one embodiment, 78 % of said particle diameters have a 88 nm average diameter. In one embodiment, 22% of said particle diameters have a 27 nm average diameter. In one 25 embodiment, 84% of said particle diameters have a 90 nm average diameter. In one embodiment, 16% of said particle diameters have a 23 nm average diameter. In one embodiment, 80% of said particle diameters have a 55 nm average diameter.
In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a premix comprising a compound, a first antioxidant, a second 30 antioxidant, and an aqueous dispersion medium, wherein said compound has a solubility greater than 30 mg/ml in said medium; and iii) a microfluidizer capable of maintaining at 3 WO 2008/010788 2013200590 05 Feb 2013 PCT/US2006/026918 least 25,000 PS1; c) using a single pass exposure of said premix to said microiluidizer to create a population of nanoemulsion particles having diameters ranging from between approximately 40-110 nm, wherein said particle diameter remains stable for at least four months. In one embodiment, the method further comprises pasteurizing said 5 population of nanoemulsion particles wherein said particle diameters remain stable. In one embodiment, the method further comprises freezing said population of nanoemulsion particles wherein said particle diameters remain stable.
In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a stable aqueous dispersion medium comprising a first antioxidant; ii) a 10 solution comprising natural emulsifiers; ii) a compound having substantial solubility in said medium comprising a second antioxidant; and iii) a microiluidizer capable of making a uniform nanoemulsion from said medium; b) adding said compound and said solution to said medium and heating to a temperature of at least 50°C to create a premix; and c) microfluidizing said premix at a pressure of at least 25,000 PSI to create said 15 nanoemulsion having particle diameters ranging between 40 -110 nm wherein said particle diameter remains stable for at least four months. In one embodiment, the nanoemulsion encapsulates the compound. In one embodiment, the method further comprises pasteurizing said nanoemulsion wherein said particle diameters remain stable. In one embodiment, the method further comprises freezing said nanoemulsion wherein 20 said particle diameters remain stable. In one embodiment, said solution comprises milk. In one embodiment, said compound comprises DHA fish oil. In one embodiment, said pasteurization comprises exposing said nanoemulsions to 75°C for thirty seconds. In one embodiment, said freezing comprises exposing said nanoemulsions to - 4°C for 24 hours.
In one embodiment, the present invention contemplates a method, comprising; 25 a) providing; i) a subject refractory to an administered compound at a therapeutically effective amount; ii) a nanoemulsion comprising a population of particles encapsulating said compound, wherein said particles having diameters between approximately 10 and approximately 110 nanometers, wherein said nanoemulsion is not contaminated by particles having diameters larger than 110 nanometers; b) delivering said nanoemulsion 30 to said patients under conditions such that said compound bioavailability is improved and wherein said compound is therapeutically effective. In one embodiment, the improved 4 WO 2008/010788 2013200590 05 Feb 2013 PCT/US2006/026918 bioavailability compnses pharmacokinetic parameters selected trom me group consisting of decreased Tmax, increased C^x, and increased AUC, In one embodiment, the delivering comprises a method selected from the group consisting of oral, transdermal, intravenous, intraperitoneal, intramuscular, and subcutaneous. In one embodiment, the 5 nanoemulsion comprises a plant sterol. In one embodiment, the nanoemulsion comprises lycopene.
In one embodiment, the present invention contemplates a method for improving a nanoemulsion bioavailability comprising providing a uniform microfluidized nanoemulsion and delivering the uniform nanoemulsion to a subject. In one embodiment, 10 the subject comprises a mammal. In one embodiment, the nanoemulsion encapsulates a compound. In one embodiment, the nanoemulsion is delivered by oral administration. In another embodiment, the nanoemulsion is delivered by methods including, but not limited to, transdermally, intravenously, intraperitoneally, intramuscularly or subcutaneously. In one embodiment, said improved bioavailability comprises 15 pharmacokinetic parameters selected from the group consisting of decreased Tmax, increased Cmax, and increased AUC. In one embodiment, said nanoemulsion is formulated for oral administration. In one embodiment, said nanoemulsion comprises a plant sterol. In one embodiment, said nanoemulsion comprises lycopene.
In one embodiment, the present invention contemplates a nanoemulsion having 20 bacteria-resistant properties, wherein said nanoemulsion comprises a population of particles encapsulating said compound, wherein said particles having diameters between approximately 10 and approximately 110 nanometers, wherein said nanoemulsion is not contaminated by particles having diameters larger than 110 nanometers. In one embodiment, the nanoemulsion resists bacterial growth for at least three months. In one 25 embodiment, the bacterial-resistant properties comprise shear-force induced cell lysis. In one embodiment, the bacterial-resistant properties comprise an oxidizing environment.
In one embodiment, the nanoemulsion is sterile.
In one embodiment, die present invention contemplates a uniform microfluidized nanoemulsion comprising bacteria-resistant properties. In one embodiment, said 30 nanoemulsion resists bacterial growth for at least three months. In one embodiment, the nanoemulsion comprises particles having a diameter distribution of between 10-110 5 WO 2008/010788 2013200590 05 Feb 2013 PCT/US2006/026918 nm. In one embodiment, said bacterial-resistant properties compose shear-force induced cell lysis. In one embodiment, the nanoemulsion is sterile.
In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a premix comprising a compound and a liquid dispersion medium; and 5 ii). a device capable of creating a continuous turbulent flow under high pressure; b) using said device to create a population of nanoemulsion particles having uniform diameter. In one embodiment, the dispersion medium is selected from the group consisting of aqueous media and oil-based media. In one embodiment, the aqueous media is selected from the group consisting of water, saline solution, ringers solution, dextrose, and short chain 10 alcohols. In one embodiment, the oil-based media is selected from the group consisting of saturated and unsaturated oils from vegetable and marine sources, silicone oils, and mineral oils. In one embodiment, the compound is selected from the group consisting of a plant sterol, cod liver oil, tocopherol, lecithin, lutein, zeaxanthin, and soy protein. 15 Definitions
In general, the terms used herein are to be interpreted according to definitions generally accepted by those having ordinary skill in the art. Those listed below, however, are to be interpreted according to the following definitions.
The term “microfluidized”, “microfluidizing”, or “microfluidizer” as used herein 20 refers to an instrument or a process that utilizes a continuous turbulent flow at high pressure including, but not limited to, a microfluidizer or other like device that may be useful in creating a uniform nanoemulsion. For example, microfluidizing may create a uniform nanoemulsion comprising a pharmaceutical, nutraceutical, or cosmeceutical from a premix within a thirty (30) second time frame (typically referred to a single pass 25 exposure). Typically, a microfluidizer may be operated at a pressure of approximately 25,000 PSI to generate a uniform nanoemulsion.
The term “uniform nanoemulsion” as used herein, refers to any emulsion comprising any specified range of particle diameter sizes wherein the difference between the minimum diameter and maximum diameters do not exceed approximately 600 nm, 30 preferably approximately 300 nm, more preferably approximately 200 nm, but most preferably approximately 100 nm (i.e., for example, microfluidization, as contemplated 6 WO 2008/010788 2013200590 05 Feb 2013 PCT/US2006/026918 herein, produces a uniform nanoemulsion having a range of approximately 10 -110 nm and is referred to herein as a uniform microfluidized nanoemulsion). Preferably, the total particle distribution (i.e., 100%) is encompassed within the specified range of particle diameter size. Λ particle diameter distribution where less than 3% is outside the 5 specified range of particle diameter sizes is still contemplated herein as a uniform nanoemulsion.
The term “population” as used herein, refers to any mixture of nanoemulsion particles having a distribution in diameter size. For example, a population of nanoemulsion particles may range is particle diameter from between approximately 10 -10 llOnm.
The term “nanoparticle” as used herein, refers to any particle having a diameter of less than 300 nanometers (nm), as defined by the National Science Foundation or preferably less than 100 nm, as defined by the National Institutes of Health. Most conventional techniques create nanoparticle compositions with an average particle 15 diameter of approximately 300 nanometers (nm) or greater.
The term “dispersion medium” as used herein, refers to any oil-based or aqueous liquid wherein a pharmaceutical, nutraceutical, or cosmeceutical may be dissolved upon heating. Oil-based liquids may include, but not limited to; saturated and unsaturated oils from vegetable and marine sources including, but not limited to, soybeans, safflowers, 20 olives, com, cottonseeds, linseed, safflower, palm, peanuts, flaxseeds, sunflowers, rice bran, sesame, rapeseed, cocoa butter etc., and mixtures thereof; silicone oils; and mineral oils. Alternatively, aqueous media may include, but are not limited to, water, saline solutions, short chain alcohols, 5% dextrose, Ringer's solutions (lactated Ringer's injection, lactated Ringer's plus 5% dextrose injection, acylated Ringer's injection), 25 Normosol-M, Isolyte E, and the like; and synthetic and/or natural detergents having high surfactant properties, deoxycholates, cyclodextrins, chaotropic salts and ion pairing agents etc., and mixtures thereof.
The term “compound” as used herein, refers to any pharmaceutical, nutraceutical, or cosmeceutical (i.e., for example, organic chemicals, lipids, proteins, oils, vitamins, 30 crystals, minerals etc.) that are substantially soluble in a dispersion medium. 7 WO 2008/010788 2013200590 05 Feb 2013 PCT/US2006/026918
The term “substantially soluble” as used herein, refers to any compound that dissolves into a dispersion medium to a concentration greater than 30 mg/ml. Preferably, the dispersion medium is heated while the compound is being dissolved. ITre term “premix” as used herein, refers to any mixture that is subsequently used 5 to generate a nanoparticulate composition or a uniform microfluidized nanoemulsion. Typically, premixes contain a liquid dispersion médium and a compound, and optionally, an emulsifier and/or an antioxidant.
The term “stable” as used herein, refers to any population of nanoemulsion particles whose diameters stay within the range of approximately 10 -110 nm over a 10 prolonged period of time (i.e„ for example, one (1) day to twenty-four (24) months, preferably, two (2) weeks to twelve (12) months, but more preferably two (2) months to five (5) months). For example, if a population of nanoemulsion particles is subjected to prolonged storage, temperature changes, and/or pH changes whose diameters stay within a range of between approximately 10-110 nm, the nanoemulsion is stable. 15 The term “bacteria-resistant” as used herein refers to the lack of observable bacterial growth.
The term “sterile” as used herein refers to a nanoemulsion that contains no living bacterial cells.
The term "pharmaceutically acceptable" as used herein, refers to those 20 compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The term "pharmaceutically acceptable salts" as used herein, refers to derivatives 25 wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound 30 formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as 8 WO 2008/010788 2013200590 05 Feb 2013 PCT/US2006/026918 hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic* pamoic, maleic, hydioxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, 5 methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
The term "therapeutically effective amount" as used herein, with respect to a drug dosage, shall mean that dosage that provides the specific pharmacological response for which the drug is administered or delivered to a significant number of subjects in need of such treatment. It is emphasized that 'therapeutically effective amount,' administered to 10 a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a "therapeutically effective amount" by those skilled in the art. Specific subjects may, in fact, be “refractory” to a “therapeutically effective amount”. For example, a refractory subject may have a low bioavailability such that clinical efficacy is not obtainable. It is to be further understood 15 that drug dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
The term “refractory” as used herein, refers to any subject that does not respond with an expected clinical efficacy following the delivery of a compound as normally observed by practicing medical personnel. 20 The term “delivering" or “administering” as used herein, refers to any route for providing a pharmaceutical or a nutraceutical to a subject as accepted as standard by the medical community. For example, the present invention contemplates routes of delivering or administering that include, but are not limited to, oral, transdermal, intravenous, intraperitoneal, intramuscular, or subcutaneous. 25 The term “subject” as used herein, refers to any animal to which an embodiment of the present invention may be delivered or administered. For example, a subject may be a human, dog, cat, cow, pig, horse, mouse, rat, gerbil, hamster etc.
The term "encapsulate”, “encapsulated”, or “encapsulating” refers to any compound that is completely surrounded by a protective material. For example, a 30 compound may become encapsulated by a population of nanoemulsion particle formation during microfluidization. 9 WO 2008/010788 2013200590 05 Feb 2013 PCT/US2006/026918
The term “nutraceutical” refers to any compound added to a dietary source (i.e., for example, a fortified food or a dietary supplement) that provides health or medical benefits in addition to its basic nutritional value.
The term “cosmeceutical” refers to any compound (i.e., for example, benzoyl 5 peroxide or retinol) added to a preparation that possesses both cosmetic and pharmaceutical properties. A cosmecuetical is generally useful for external applications to improve the complexion or overall physical appearance. Cosmeceuticals may be applied as compositions including, but not limited to, a cream, oil, foam, spray, liquid etc. Cosmeceuticals may include categories such as, but not limited to, carotenoids, phenolic 10 compounds, or water soluble antioxidants.
Brief Description Of The Figures
Figure 1 presents exemplary data showing the particle diameter distribution of a microfluidized plant sterol nanoemulsion population three (3) months after preparation. 15 Figure 1A presents exemplary data showing the particle diameter distribution of a microfluidized plant sterol nanoemulsion three (3) months after preparation.
Figure 2 presents exemplary data showing the particle diameter distribution of a microfluidized cod liver oil nanoemulsion population four (4) months after preparation.
Figure 3 presents exemplary data showing the particle diameter distribution of a 20 microfluidized tocopherol nanoemulsion population five (5) months after preparation.
Figure 4 presents exemplary data showing the particle diameter distribution of a microfluidized lutein/zeaxanthin nanoemulsion population.
Figure 5 presents exemplary data showing the particle diameter distribution of a microfluidized soy protein nanoemulsion population. 25 Figure 6 presents exemplary data showing the particle diameter distribution of a microfluidized whey protein nanoemulsion population.
Figure 7 presents exemplary data showing the particle diameter distribution of a microfluidized orange juice/plant sterol/lutein nanoemulsion population.
Figure 8 presents exemplary data showing the particle diameter distribution of a 30 microfluidized DHA fish oil/water nanoemulsion population two (2) months after preparation. 10 WO 2008/010788 2013200590 05 Feb 2013 PCT/US2006/026918
Figure 9 presents exemplary data showing the particle diameter distribution of a microfluidized DHA fish oil/milk nanoemulsion population three (3) weeks after preparation.
Figure 10 presents exemplary data showing the particle diameter distribution of a 5 microfluidized DHA fish oil/milk/tocopherol nanoemulsion population.
Figure 11 presents exemplary data showing the particle diameter distribution of a microfluidized DHA fish oil/milk/tocopherol nanoemulsion population after pasteurization.
Figure 12 presents exemplary data showing the particle diameter distribution of a 10 microfluidized DHA fish oil/milk/tocopherol nanoemulsion population after a freeze-thaw process.
Figure 13 presents exemplary data of gerbil plasma lycopene levels when fed a lycopene-enriched diet.
Figure 14 presents exemplary data of gerbil plasma lycopene levels when fed a 15 microfluidized lycopene nanoemulsion diet.
Figure 15 presents one embodiment of an anti-bacterial property generated during the preparation of a microfluidized plant sterol nanoemulsion
Figure 16 presents exemplary data showing the particle diameter distribution of a microfluidized plant sterol nanoemulsion population used in Example 12. 20 Figure 17 presents exemplary data showing that a microfluidized plant sterol nanoemulsion diet is more effective in reducing plasma LDL-C in hypercholesterolemic hamsters than either a micronized plant sterol diet or a crystalline plant sterol diet for four (4) weeks.
Figure 18 presents exemplary data comparing premix cholesterol particle l 25 diameter distributions from: Panel A: Tween® 80/Water as per the * 118 patent; and Panel B: Oil/Lecithin/Tween® 80/Water as contemplated by one embodiment of the present invention.
Figure 19 presents exemplary data comparing microfluidized cholesterol nanoemulsion particle diameter distributions from: Panel A: Tween® 80/Water as per the 30. ‘118 patent using repeated microfluidization passes; and Panel B: Oil/Lecithin/Tween® 11 PCT/US2006/026918 WO 2008/010788 80/Water as contemplated by one embodiment of the present invention using a single microfluidization pass.
Figure 20 presents exemplary data comparing microfluidized cholesterol nanoemulsion particle diameter distributions from: Panel A: Tween® 80/Water as per the ‘118 patent using a single pass exposure; and Panel B: Oil/Lecithin/Tween® 80/Water as contemplated by one embodiment of the present invention using a single pass exposure.
Detailed Description Of The invention
The present invention relates to the field of nanoemulsions. In one embodiment, the nanoemulsion is created by a high shear stress technology. In one embodiment, the invention comprises uniform microfluidized nanoemulsions. In another embodiment, the uniform nanoemulsion comprises a compound such as a pharmaceutical, nutraceutical, or cosmeceutical. In one embodiment, the uniform nanoemulsion comprises improved pharmacokinetic parameters when compared to conventional nanoparticulate compositions and/or nanoemulsions. In one embodiment, the present invention contemplates a method of making a bacteria-resistant nanoemulsion.
The use of nanoemulsions as a delivery system is generally directed to pharmaceuticals. Nanoemulsion nutraceutical delivery, however, has received little attention. For example, one nanoemulsion system contains plant sterols. Bruce et al, “Method for producing dispersible sterol and stanol compounds” US Pat. No, 6,387,411 (2002)(herein incorporated by reference). This technology, however, uses a grinding method to produce the nanoemulsions, and consequently, the particle diameter is at least six (6) times greater than contemplated herein. Although it is not necessary to understand the mechanism of an invention, it is believed that this diameter difference offers particular advantages in stability and efficacy (infra). Further, the ‘411 patent does not disclose the incorporation of absorbable micronutrients. A further use of nanoemulsions as a delivery system is directed to cosmeceuticals. Cosmeceuticals may comprise, for example; carotenoids including, but not limited to, a-carotene, β-carotene, β-cryptoxanthin, lycopene, crocetin, fucoxanthin, halocynthiaxanthin, canthaxanthin, astraxanthin, lutein, or zeaxanthin; phenolic compounds including, but not limited to, quercetin, rutin, myricetin, kaemferol, catechin, 12 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 epigallocatechin, epicatechin, reservatrol, tocopherol, ferulate, ubiquinol-10, soy isoflavones such as genestein, daidzein, alpha lipoic acid, anthocyanins, ellagic tannins, gallic or ellagic acids; or water soluble anti-oxidants such as ascorbic acid, uric acid, or bilirubin. 5 The present invention is directed to populations of nanoparticles or nanoemulsions comprising an oral delivery vehicle for all absorbable (i.e., for example, fat-soluble) nutrients including, but not limited to, fatty acids, carotenoids, tocophérols, tocotrienols, and coenzyme-Q. Delivery methods, however, are not limited to oral and include, but are not limited to, transdermal, intravenous, intraperitoneal, intramuscular, or 10 subcutaneous. In another embodiment, the carotenoids include, but are not limited to, lutein and zeaxanthin. The present invention is also directed to populations of nanoparticles or nanoemulsions comprising an oral delivery vehicle for all nonabsorbable (i.e., for example, fat soluble) plant sterol compounds including, but not limited to, phytosterols and phytostanols. In one embodiment, the compounds are 15 encapsulated by the nanoparticles or nanoemulsions. In one embodiment, common emulsifying agents are used to prepare the nanoemulsions. In one embodiment, the emulsifying agents include, but are not limited to, phospholipids, fatty acid monoglycerides, fatty acid diglycerides, or polysorbates.
The present invention also contemplates that certain nanoemulsion embodiments 20 .of the present invention comprise a surface-to-volume ratio that results in an improved bioavailability over current methods and compositions known in the art.
The present invention also contemplates that certain nanoemulsion embodiments of the present invention are resistant to microbiological growth. Although it is not necessary to understand the mechanism of an invention, it is believed that the 25 ' microfluidization process comprises a high sheer stress and/or creates an oxidizing environment, thereby disrupting microbial integrity and/or preventing microbial growth. I. Methods Of Making Nanoemulsions
Nanoemulsions have been generated by a variety of methods. In particular, these methods provide a wide variation in particle diameter and require organic solvents and or 30 polymers. When these known nanoemulsions are considered for an oral drug or nutrient 13 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 delivery system, issues of biocompatibility and physiological side effects become an important issue.
In one embodiment, the present invention contemplates a method of making a nanoemulsion comprising a continuous turbulent flow at high pressure. In one 5 embodiment, the high pressure turbulent flow comprises microfluidization, hi one embodiment, a uniform nanoemulsion is generated from a premix using a single pass exposure (i.e., for example, within a thirty (30) second time frame). In one embodiment, the uniform nanoemulsion comprises a population of particles whose difference between the minimum and maximum diameters does not exceed approximately 100 nm. In one 10 embodiment, a uniform nanoemulsion is generated using a pressure of at least 25,000 PSI. In one embodiment, the present invention contemplates a method of making uniform microfluidized nanoemulsions without organic solvents or polymers. In one embodiment, the microfluidized nanoemulsion is made from a suspension. In another embodiment, the microfluidized nanoemulsion is made from a microemulsion. 15 In one embodiment, the present invention contemplates a uniform microfluidized nanoemulsion using compounds that are substantially soluble in a liquid dispersion medium. In one embodiment, the nanoemulsion encapsulated the compounds. In one embodiment, the compounds comprise pharmaceuticals and/or nutraceuticals.
Exemplary nutraceuticals and dietary supplements are disclosed, for example, in 20 Roberts et al., Nutriceuticals: The Complete Encyclopedia of Supplements, Herbs, Vitamins, and Healing Foods (American Nutriceutical Association, 2001), which is specifically incorporated by reference. Dietary supplements and nutraceuticals are also disclosed in Physicians' Desk Reference for Nutritional Supplements, 1st Ed. (2001) and The Physicians' Desk Reference for Herbal Medicines, 1st Ed. (2001), both of which are 25 also incorporated by reference. A nutraceutical or dietary supplement, also known as a phytochemical or functional food, is generally any one of a class of dietary supplements, vitamins, minerals, herbs, or healing foods that have medical or biological effects on the body.
Exemplary nutraceuticals or dietary supplements include, but are not limited to, 30 lutein, folic acid, fatty acids (e.g., DHA and ARA), fruit and vegetable extracts, vitamin and mineral supplements, phosphatidylserine, lipoic acid, melatonin, 14 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 glucosamine/chondroitin, Aloe Vera, Guggul, amino acids (e.g., glutamine, arginine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), green tea, lycopene, whole foods, food additives, herbs, phytonutrients, antioxidants, flavonoid constituents of fruits, evening primrose oil, flax seeds, fish and marine animal 5 oils, and probiotics. Nutraceuticals and dietary supplements also include bio-engineered foods genetically engineered to have a desired property, also known as "pharmafoods."
In particular, these compounds include, but are not limited to, naturally occurring oils, fatty acids, and proteins. In one embodiment, a naturally occurring oil comprises fish oil (i.e., for example, cod liver oil). In one embodiment, a naturally 10 occurring fatty acid comprises an omega-3 (i.e., for example, DHA). In one embodiment, the nanoemulsion comprises little or no fat. In one embodiment, a naturally occurring protein comprises soy or whey.
In one embodiment, the present invention contemplates a method of making a uniform microfluidized nanoemulsion comprising a population of particles whose 15 diameter ranges from between 10- llOnm. A. The Microfluidizer
Microfluidization is a unique process that powers a single acting intensifier pump. The intensifier pump amplifies the hydraulic pressure to the selected level which, in turn, imparts that pressure to the product stream. As the pump travels through its pressure 20 stroke, it drives the product at constant pressure through the interaction chamber. Within the interaction chamber are specially designed fixed-geometry microchannels through which the product stream will accelerate to high velocities, creating high shear and impact forces that generates a uniform nanoemulsion as the high velocity product stream impinges on itself and on wear-resistant surfaces. 25 As the intensifier pump completes its pressure stroke, it reverses direction and draws in a new volume of product. At the end of the intake stroke, it again reverses direction and drives the product at constant pressures, thereby repeating the process.
Upon exiting the interaction chamber, the product flows through an onboard heat exchanger which regulates the product to a desired temperature. At this point, the 30 product may be recirculated through the system for further processing or directed externally to the next step in the process. Cook et al., “Apparatus For Forming 15 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013
Emulsions” US Pat No. 4,533,254 (1985); and Cook et al., “Method Of Forming A Microemulsion” US Pat No. 4,908,154 (1990)(both herein incoiporated by reference). B. Nanoparticulate Compositions
Early attempts using microfluidizers to create nanoparticulate compositions 5 required drug substances that were poorly soluble in a liquid dispersion medium. In one disclosed technology, “poorly soluble” was defined as less than 10 mg/ml. Bosch et al., “Process for preparing therapeutic compositions containing nanoparticles” US Pat No. 5,510,118 (1996)(herein incorporated by reference). While water-insolubility was preferably considered, oil-insoluble compounds were also subjected to a 10 microfluidization process. The ‘118 patent’s microfluidization process is described as a “milling” action, thus indicating that the insoluble compound particles are undergoing a physical disintegration during the creation of the nanoparticulate composition. Further, this previous process requires long-processing times (i.e., repeated microemulsifying cycles) thereby promoting heat build-up in the microfluidizer. Consequently, this early 15 technique requires processing temperatures of less than 40°C. One problem is that this technique resulted in average nanoemulsion particle diameters of approximately 300 nm. Despite teachings within the ‘118 patent that lower particle diameters (i.e., less than 100 nm) can be achieved, no data is presented demonstrating such a capability. Exemplary data presented herein has used the Bosch et al. process to produce a complete particle 20 diameter distribution profile. See Example 13. These data show that the Bosch et al. technology cannot produce a uniform nanoemulsion as contemplated by the present invention.
Several others have implemented the basic ‘118 technology to encapsulate various insoluble compounds. In fact, these subsequent disclosures define a nanoparticle 25 composition as “particles consisting of a poorly soluble therapeutic or diagnostic agent having adsorbed onto, or associated with, the surface thereof anon-crosslinked surface stabilizer”. Cooper et al., “Nanoparticulate Sterol Formulations And Novel Sterol Combinations” United States Patent Application Publication No. 2004/0033202 Al (2004)(see pg I para 3)(herein incorporated by reference). Like the ‘ 118 patent, Cooper 30 et al. discloses preparing nanoparticulate compositions using compounds that are poorly soluble in a liquid dispersion medium (i.e., water, oils, alcohols, glycols, etc.). For 16 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 example, Cooper et al. defines a “poorly water-soluble” drug as having a solubility of less than about 30 mg/ml. For example, plant sterol nanoparticulate compositions comprising one or more sterols or stands (i.e., sitosterol or phytosterols) are suggested in the art as having a particle diameter of less than 50 nm. Cooper et al. does not use a microfluidizer 5 nor present any data showing a capability of providing a uniform particle diameter ranging between 10-110 nm. Instead, Cooper et al. relies upon a more traditional milling process that does not produce a uniform particle diameter distribution ranging between 10-110 nm.
Cooper et al. employs a milling grinder known in the art as a DYNO®-MILL 10 KDL. This equipment is currently marketed in the United States by Glen Mills, Inc. (Clifton, NJ) and advertises with the following technical information. The DYNO®-MILL is a versatile horizontal bead mill having applications ranging from paints and coatings to drug manufacturing and cell disruption for extracting proteins. Grinding to a mean diameter of320 nm has been reported in research papers. Operation of the 15 DYNO®-MILL is always wet, that is, the material to be ground is held in suspension in any suitable liquid. A jacketed grinding chamber contains a series of agitators that are equally spaced along the length of a central shaft. The jacket on the grinding chamber is used to control the temperature of the material being processed. The chamber is secured at one end and cantilevers out over the shaft. The bearing end contains a separator gap 20 which has clearance tolerances that can be set as tight as 20 microns. The chamber is filled to about 80% of its capacity with beads (i.e., PolyMill® 500; 500 pm diameter grinding beads). Depending on the specific application beads made from glass, ceramic, metals, tungsten carbide and other materials are available. The process material is now introduced into the chamber. When the chamber is foil of material and beads, the 25 machine is switched on and the agitator discs rotate forcing the beads to impact over and over with the process material with hurricane-like force. This action of having thousands of separate impacts produces rapid and consistent size reduction. Batch and continuous processing can be handled in the same mill by changing the grinding chamber and the gap setting. 30 At best, Cooper et al. is limited to a plant sterol nanoparticulate composition where 90% of the particle diameters are below 187 nm. The actual particle diameter 17 PCT/US2006/026918 WO 2008/010788 distribution, however, is not presented. In one embodiment, the present invention contemplates that the technology described by Cooper et al. cannot produce a uniform particle diameter distribution ranging between 10-110 nm. See Example 14. Unlike some embodiments of the present invention, Cooper et al. has not considered methods to make a nanoparticulate composition that include a heating process. In fact, Cooper et al. presents a discussion concluding that preparing a plant sterol nanoparticulate composition using a process that includes heating is not desirable and problematic. Some embodiments of the present invention have solved those problems.
Two drugs that are insoluble in a selected liquid dispersion medium, meloxicam and topiramate, are suggested as potential candidates for improved clinical administration using the Cooper et al. nanoparticulate composition technology. Cooper et al., “Nanoparticulate meloxicam formulations” US Pat. Appln Publ. No. 2004/0229038 (2004) ; and Gustow et al., “Nanoparticulate topiramate formulations” US Pat. Appln Publ. No. 2004/0258758 (2004). Neither publication contains any exemplary data demonstrating the creation of a uniform microfluidized microemulsion having a particle diameter range of about 10-110 nm. C. Nano emulsification
The formation of a uniform mixture (i.e., for example, a population) of predominantly small particles may involve a physical process termed “emulsification”.
An emulsion is traditionally defined in the art “as a system ... consisting of a liquid dispersed with or without an emulsifier in an immiscible liquid usually in droplets of larger than colloidal size” Medline Plus Online Medical Dictionary, Merriam Webster (2005) . Consequently, as the art developed emulsifiers capable of generating smaller and smaller diameter particles, the terms “microemulsion” and “nanoemulsion” became known. Conceptually, a microemulsion is one thousand-fold greater in diameter than a nanoemulsion. However, particle diameter distributions may vary widely in a non-controlled emulsification process creating considerable overlap between the nanoemulsion and microemulsion technologies.
In one embodiment, the present invention contemplates a premix comprising a compound substantially soluble (i.e., for example, greater than 30 mg/ml) in a liquid dispersion medium (i.e., for example, a heated liquid dispersion medium) and, optionally, 18 WO 2008/010788 2013200590 05 Feb 2013 PCT/US2006/026918 common emulsifying agents including, but not limited to, phospholipids, fatty acid monoglycerides, fatty acid diglycerides, or polysorbates. In one embodiment, a nanoemulsion is created by exposing a premix to a continuous turbulent flow at a high pressure, wherein the pressure is at least 25,000 PSI. In one embodiment, the high 5 pressure turbulent flow comprises microfluidization. In one embodiment, the nanoemulsion comprises particles encapsulating pharmaceuticals or nutraceuticals. In one embodiment, the nanoemulsion comprises a uniform nanoemulsion having stable particles. In one embodiment, the microfluidization comprises a single pass exposure J (i.e., for example, approximately thirty (30) seconds). In one embodiment, a uniform 10 plant sterol microfluidized nanoemulsion has an improved low density lipoprotein cholesterol lowering efficacy.
Oral drag administration is a common method for providing pharmaceuticals and nutraceuticals to any subject. The contemplated methods of delivering a nanoemulsion is not limited to oral and include, for example, transdermal, intravenous, intraperitoneal, 15 intramuscular, or subcutaneous routes of administration. Oral administration is favored because the formulations (i.e., liquids or suspensions) are relatively inexpensive to produce and are well tolerated. Subsequent gastrointestinal absorption of the formulation’s ingredients, however, is not as predictable. For the pharmaceuticals and nutraceuticals to gain entrance into the subject, the formulations must be compatible with 20 the digestive system. Consequently, lipid-based drug delivery systems are known to be useful as carriers for many drug delivery systems. Their efficacy, however, maybe dependent upon; i) lipid composition (i.e., for example, molecular size and charge); ii) pharmaceutical, nutraceutical, or cosmeceutical chemical structure (i.e., molecular size and pH ionization); and iii) the overall health of the subject. Lipids are generally 25 categorized as physiologically non-absorbable or absorbable. It should be recognized that gastrointestinal absorption processes are unrelated to a compound’s solubility properties. The present invention contemplates compositions arid methods related to uniform microfluidized nanoemulsions comprising either absorbable or non-absorbable lipids thereby improving their bioavailability. 30 19 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 1. Non-Absorbable Lipids
Plant sterols, stanols, and triterpene alcohols (i.e., for example, oryzanol) are either not absorbed, or poorly absorbed, into the bloodstream following oral administration. In one embodiment, the present invention contemplates a method of 5 making a uniform nanoemulsion (i.e., for example, microfluidized) comprising a nonabsorbable lipid having substantial solubility in a liquid dispersion medium and, optionally, common emulsifying agents, such as phospholipids, fatty acid monoglycerides, fatty acid diglycerides, or polysorbates to formulate improved nanoemulsions. In one embodiment, the nanoemulsion comprises particle diameters 10 ranging between 10-110 nm, thereby improving oral administration.
The use of plant sterols, such as β-sitosterol, is known to reduce blood cholesterol levels because it is non-absorbable. The presence of unabsorbed plant sterols in the / gastrointestinal system inhibits the normal metabolism of cholesterol and, concomitantly, decreases blood cholesterol levels. Specifically, administration of twenty (20) gms of 15 crystalline plant sterols can reduce plasma cholesterol levels approximately 10%. Pollack et al., “Sitosterol”. In: Monographs on Atherosclerosis. Vol. 10, Eds. O.J. Pollack & D. Kritchevsky, Basel, New York., Karger (1981).
Further, non-absorbable lipids are advantageous as a nutraceutical because of a lack of side effects. Side effects are routinely observed when using traditional 20 pharmaceutical systemic cholesterol-lowering interventions (i.e., for example, HMG CoA reductase inhibitors or niacin). Because of the very low incidence of side effects, plant sterols can be prescribed for the general population, including children for whom systemic interventions are rarely recommended. It is known that the consumption of adequate amounts of plant sterols will lower blood cholesterol levels. The present 25 invention contemplates improvements in currently known methods to deliver plant sterols or stanols.
The first known method involves dissolving the plant sterol in a vegetable oil-containing margarine to an efficacious level of plant sterol. When the fat solubility of a free stand or a sterol is increased by: i) interesterified with a fatty acid such oleate or 30 linoleate; ii) mixed in vegetable oil; or iii) hydrogenated to produce margarine, plasma cholesterol can be reduced by approximately 30%. To ingest enough plant sterol, this 20 PCT/US2006/026918 WO 2008/010788 process can result in the consumption of up to approximately eighteen (18) grams of fat. Miettinen et al., “Use of a stanol fatty acid ester for reducing serum cholesterol level” US Patent Mo. 5,502,045 (1996); and Wester et al., “Phytosterol compositions” US Patent No. 6,589,588 (2003)(both herein incoiporated by reference). To fat conscious Americans, coupled with the high cost of the margarines, this is unacceptable for a naturopathic approach to lower plasma cholesterol. A disadvantage of this method is that overweight or obese people frequently have elevated cholesterol levels. Physicians, of course, caution this subject group to avoid additional dietary fat. In one embodiment, the present invention contemplates a method of making a beverage nanoemulsion that comprises plant sterols. For example, the method to make the beverage nanoemulsion may comprise a continuous turbulent flow at a high pressure. In one embodiment, the continuous turbulent high pressure flow comprises microfluidization. In another embodiment, the nanoemulsion beverage comprises an orange juice product.
The second known method comprises oral delivery of water-dispersible plant sterols (i.e., for example, a stanol not dissolved in fat) by incorporation micron-sized micelles (i.e., microemulsions having diameters of several thousand nanometers) which can be subsequently added to beverages or foods. Ostlund, Jr., “Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same” US Patent No. 5,932,562 (1999)(herein incoiporated by reference). When the microemulsion containing the plant sterol was administered into the intestine, cholesterol absorption was reduced by approximately 37%. Ostlund, Jr., “Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same” US Patent No. 5,932,562 (1999)(herein incorporated by reference); and Spillburg et al., “Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterol” J Am Diet Assoc. 103:577-581 (2003). A disadvantage of this method is that the particle diameters of these microemulsion preparations are on the order of thousands of nanometers (i.e., micron diameters) and thereby does not provide optimal efficacy.
The present invention contemplates a nanoemulsion technology comprising a specific formulation and a microfluidization process that provides particle diameters from between 10-110 nm. In one embodiment, the nanoparticle has improved pH and 21 PCT/ÜS2006/026918 WO 2008/010788 2013200590 05 Feb 2013 temperature stability properties, thereby stabilizing the particle’s integrity throughout the gastrointestinal system.
The third known method involves the oral delivery of plant sterols by producing a water dispersible sterol product. These water dispersible products usually include 5 emulsifying agents including, but not limited to, monoglycerides and polysorbates.
These water dispersible products are known to be homogenized using a liquid/liquid dispersion having particle diameters less than 1000 nm (mean = 358 nm). The present invention, however, contemplates a microfluidizing nano emulsion technology (i.e., for example, that produced by a continuous flow high pressure process) that improves the 10 emulsification of these water-dispersible plant sterols into nanoemulsions having a particle diameter of approximately 40-60 nm.
Similarly, methods are known for preparing water dispersible sterol/stanol or sterol/stanol ester compositions by co-melting the stanol/sterols with highly branched hydrocarbons and then grinding the resulting product. Bruce et al., “Method for 15 producing dispersible sterol and stand compounds” US Patent No. 6,387,411 (2002)(herein incorporated by reference). This grinding method typically produces particle diameters ranging from 10-150 microns. Other methods known to produce a water dispersible sterol product use homogenization in emulsifying agents including, but not limited to, monoglycerides and polysorbates. These homogenization procedures have 20 been reported to produce a liquid/liquid dispersion with a particle diameter less than 1000 nm (mean = 358 nm). Stevens et al., “Aqueous dispersible sterol product” US Patent No. 6,623,780 (2003)(herein incorporated by reference). This preparation, when added to orange juice, can reduce LDL cholesterol by approximately 12%. Devaraj et al., “Plant sterol-fortified orange juice effectively lowers cholesterol levels in mildly 25 hypercholesterolemic healthy individuals” Arterioscler Thromb Vase Biol. 24:25-28 (2004).
Although it is not necessary to understand the mechanism of an invention, it is believed that a much greater surface-to-volume ratio is reached in the uniform microfluidized nanoemulsion preparations made according to the present invention (i.e., 30 for example, up to 6 fold) and results in greater stability. Consequently, it is further believed that, any incorporated pharmaceutical, nutraceutical, or cosmeceutical has 22 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 improved efficacy (i.e., for example, plasma cholesterol lowering by a plant sterol). It is further believed that a smaller-sized plant sterol-containing nanoparticles contemplated by one embodiment of the present invention, when compared to known micron-sized micelles or microemulsions, has an improved disruption of the normal micellar delivery 5 of dietary cholesterol to the digestive tract. For example, it is known that pre-formed micron-size micelles containing plant stands were up to three (3) times more efficacious in inhibiting cholesterol absorption than a suspension of crystalline stanol. Ostlund et al., “Sitostanol administered in lecithin micelles potently reduces cholesterol absorption in humans” Am J Clin Nutr 70:826-831 (1999). 10 2. Absorbable Lipids
This invention also relates to the use of nanoemulsions as an oral delivery vehicle for absorbable lipids including, but not limited to, fatty acids, carotenoids, tocopherols and other fat soluble vitamins, tocotrienols, and Coenzyme-Q. In one embodiment, the present invention contemplates a method to make a uniform microfluidized nanoemulsion IS comprising an absorbable lipid having substantial solubility in a liquid dispersion medium and, optionally, common emulsifying agents, such as phospholipids, fatty acid monoglycerides, fatty acid diglycerides, or polysorbates to formulate improved « nanoemulsions. In one embodiment, the method comprises a step exposing a premix to a continuous turbulent flow at high pressure. In one embodiment, the pressure is at least 20 25,000 PSI. In one embodiment, the nanoemulsion comprises carotenoids, including, but not limited to, lutein and zeaxanthin. In one embodiment, the nanoemulsion comprises nanoparticles having a particle diameter ranging from 10-110 nm, thereby improving bioavailability. In one embodiment, nanoemulsion bioavailability is improved following oral, transdermal, intravenous, intraperitoneal, intramuscular or subcutaneous delivery. 25 In one embodiment, the present invention contemplates a method to treat or prevent macular degeneration (i.e., a major cause of blindness in people of 65) providing an improved nanoemulsion comprising at least one carotenoid. In one embodiment, the carotenoid is selected from the group comprising lutein or zeaxanthin.
Under normal physiological conditions these types of compounds may be poorly 30 absorbed by the gastrointestinal system. Consequently predicable lipid nutrient absorption is highly variable thus resulting in a highly variable lipid bioavailability (i.e., 23 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 for example, the percentage of the dose absorbed). Factors influencing bioavailability may include, but are not limited to, food processing methods, food matrix, and physiological solubility in naturally-occurring micelles (i.e., for example, the lipid micellular transport system). 5 Fat-soluble nutrients can be incorporated into high fat-containing vegetable oils for dispersal into a fat matrix (i.e., for example a micron-sized micelle). The micelle solubilizes the lipid-soluble nutrient thereby allowing absorption by the small intestine. For example, when plant sterols are delivered in a micelle, cholesterol absorption inhibition is increased up to three-fold. Ostlund et al., “Sitostanol administered in 10 lecithin micelles potently reduces cholesterol absorption in humans” Am J Clin Nutr 70:826-831 (1999).
Similarly, an increased in vitro carotenoid bioavailability in cell cultures is observed when solubilizing the carotenoids in micelles. Xu et al., “Solubilization and stabilization of carotenoids using micelles: delivery of lycopene to cells in culture” 15 Lipids 34:1031 -1036 (1999). A disadvantage of using micelles, however, involves the use of chlorinated organic solvents, a practice that should be avoided in the processing of foods stuffs. Another in vitro experiment demonstrates that a nanoemulsion preparation of lipophilic substances, such as fatty acids, vitamins, and beta-carotene can be delivered into cell culture medium (RPMI-1640) and incorporated by TK-6 cells. Zuelli et al., 20 “Delivering lipophilic substances into cells using nanoemulsions” US Patent No. 6,558,941 (2003)(herein incorporated by reference), Π. Uniform Nanoemulsion Pharmacokinetics
In one embodiment, the present invention contemplates a nanoemulsion produced by a continuous turbulent flow at high pressure having improved pharmacokinetic 25 properties when compared to conventional nanoparticulate compositions and/or nanoemulsions currently known in the art. It is known that nanoparticles deliver and/or release drugs (i.e., for example, norflaxin) and/or proteins (i.e., for example, serum albumin) more effectively than microparticles. Jeon et al., “Effect of solvent on the preparation of surfactant-free poly(DL-lactide-co-glycolide) nanoparticles and 30 norfloxacin release characteristics’ IntJPharm 207;99-108(2000); and Panyam et al., 24 PCT/XIS2006/026918 WO 2008/010788 2013200590 05 Feb 2013 “Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles” J Control Release 92:173-187 (2003).
One embodiment of the present invention contemplates a uniform microfluidized nanoemulsion having improved pharmacokinetic properties when compared to 5 conventional nanoparticulate compositions and/or nanoemulsions currently known in the art. One advantage of uniform microfluidized nanoemulsions comprises a narrow particle diameter range (i.e., for example, 10-110 nm). Most conventional nanoparticle compositions and/or nanoemulsions currently known have a wide distribution of particle diameters that interfere with the improved efficacies and bioavailabilities of the smaller 10 sized particles.
The present invention has solved the problem of generating nanoemulsions with highly variable particle diameters and provides a more uniformly small-sized nanoemulsions (i.e., for example, a uniform nanoemulsion comprising stable particles). Consequently, these uniform nanoemulsions provide improved pharmacokinetic 15 parameters when compared to conventional nanoparticle compositions and/or nanoemulsions currently known in the art independent of the mode of delivery which includes, but is not limited to, oral, transdermal, intravenous, intraperitoneal, intramuscular, subcutaneous, etc.. A. Absorption Phase 20 The use of conventional nanoparticulate compositions or nanoemulsions is not ideal due to delayed onset of action. In contrast, a uniform microfluidized nanoemulsion as contemplated by the present invention exhibits faster therapeutic effects.
Pharmaceuticals and nutraceuticals are commercially available as tablets, liquids, gel caps, capsules etc., generally intended for oral administration. Peak plasma 25 concentrations of these compositions usually occur between 2.-4 hours following administration.
When a uniform microfluidized nanoemulsion contemplated by the present invention is formulated into an oral dosage form peak plasma concentrations of an incoiporated compound can be obtained in less than about 2 hours, preferably less than 30 about 1 hour, more preferably less than about 30 minutes, but most preferably between 1 and 15 minutes. 25 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 B. Frequency of Dosing and Dosage Quantity
The recommended total daily dose of most pharmaceuticals and nutraceuticals are administered in divided doses. It is known in the art that a single daily dose may be preferable to multiple dose each day. For example, in studies of adults with partial onset 5 seizures, a daily dose of200 mg/day has inconsistent effects and is less effective than 400 mg/day. See Physicians' Desk Reference, 57.sup.th Edition, pp. 2502 (2003).
In contrast, some uniform microfluidized nanoemulsions of the present invention may be administered less frequently, at lower doses, and in dosage forms such as liquid dispersions, powders, sprays, solid re-dispersible dosage forms, ointments, creams, etc. 10 Exemplary types of formulations useful in the present invention include, but are not limited to, liquid dispersions, gels, aerosols (pulmonary and nasal), ointments, creams, solid dose forms, etc. of any pharmaceutical, nutraceutical, or cosmeceutical. Lower dosages can be used because the smaller particle diameters of embodiments of the present invention ensure more complete absorption. 15 In one embodiment, the present invention contemplates a therapeutically effective amount of a uniform microfluidized nanoemulsion having 1/6,1/5,1/4, 1/3, or 1/2 of the therapeutically effective amount of a conventional pharmaceutical, nutraceutical, or cosmeceutical formulations. C. Oral Administration 20 A liquid dosage form of a conventional nanoparticulate or nanoemulsion composition would be expected to be a relatively large volume, highly viscous substance which would not be well accepted by subject populations. Moreover, viscous solutions can be problematic in parenteral administration because these solutions require a slow syringe push and can stick to tubing. In addition, conventional formulations of poorly 25 water-soluble active agents tend to be unsafe for intravenous administration techniques, which are used primarily in conjunction with highly water-soluble substances. Embodiment contemplated by the present invention solves this problem by utilizing a liquid dispersion medium in which the pharmaceutical, nutraceutical, or cosmeceutical is substantially soluble. 3 0 Liquid dosage forms of embodiments of a uniform microfluidized nanoemulsion provide significant advantages over a liquid dosage form of a conventional 26 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 nanoparticulate or nanoemulsion. In one embodiment, the uniform microfluidized nanoemulsion comprises a low viscosity. In another embodiment, the uniform nanoemulsion comprises a silky texture. These advantages include, for example: i) better subject compliance due to the perception of a lighter formulation which is easier to 5 consume and digest; ii) ease of dispensing because one can use a cup or a syringe; iii) potential for formulating a higher concentration of a pharmaceutical, nutraceutical, or cosmeceutical resulting in a smaller dosage volume and thus less volume for the subject to consume; and iv) easier overall formulation concerns.
Liquid formulations of uniform nanoemulsions contemplated by the present 10 invention are easier to consume which is especially important when considering juvenile subjects, terminally ill subjects, and elderly subjects. Viscous or gritty formulations, and those that require a relatively large dosage volume, are not well tolerated by these subject populations. Liquid oral dosage forms can be particularly preferably for subject populations who have difficulty consuming tablets, such as infants and the elderly. 15 The viscosities of liquid dosage forms of nanoparticulate topiramate according to the invention are preferably less than about 1/200, less than about 1/175, less than about 1/150, less than about 1/125, less than about 1/100, less than about 1/75, less than about fraction 1/50, or less than about 1/25 of a liquid oral dosage form of a conventional nanoparticulate composition or nanoemulsion at about the same concentration per ml. 20 In one embodiment, the present invention contemplates a uniform microfluidized nanoemulsion that is not turbid. In one embodiment, turbid refers to the property of particul ate matter that can be seen with the naked eye or that which can be felt as "gritty" when consumed. Embodiments of nanoemulsions contemplated by the present invention can be poured out of or extracted from a container as easily as water, whereas a liquid 25 dosage form of a conventional nanoparticulate or nanoemulsion composition is expected to exhibit notably more "sluggish" characteristics. D. Increased Bioavailability
In one embodiment, the present invention contemplates a uniform microfluidized nanoemulsion having an increased bioavailability and a smaller dose requirement as 30 compared to prior conventional nanoparticulate compositions and nanoemulsions administered at the same dose. 27 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013
Any pharmaceutical, nutraceutical, or cosmeceutical can have adverse side effects if administered at a specific dose for a specific duration. Thus, lower doses which can achieve the same or better therapeutic effects as those observed with larger doses are desired. Such lower doses may be realized with a uniform microfluidized nanoemulsion 5 contemplated by the present invention due to greater bioavailability as compared to conventional nanoparticulate compositions and nanoemulsions; consequently smaller dose of pharmaceuticals and nutraceutical are likely required to obtain the desired therapeutic effect.
For example, the relative bioavailability of pharmaceutical, nutraceutical, or 10 cosmeceutical incorporated into a conventional nanoparticulate or nanoemulsion may be about 85% (i.e., as compared to a pure solution). In one embodiment, a uniform microfluidized nanoemulsion formulated into an oral pharmaceutical, nutraceutical, or cosmeceutical dosage form has a relative bioavailability preferably greater than about 85%. In other embodiments, the relative bioavailability is greater than about 90%, or 15 greater than about 95%, or greater than about 98%. E. Pharmacokinetic Profiles
The present invention also provides embodiments of uniform microfluidized nanoemulsions having incorporated pharmaceuticals and/or nutraceuticals having improved pharmacokinetic profiles when administered to mammalian subject. In one 20 embodiment, the improved profile is compared to conventional nanoparticulate compositions and nanoemulsions.
An improved pharmacokinetic (pK) profile according to the present invention can have several different types of attributes. In one embodiment, an improved pK profile of a uniform microfluidized nanoemulsion may produce the same pK profile as a 25 conventional nanoparticulate composition or nanoemulsion, but at a lower dose. In another embodiment, an improved pK profile requires less frequent dosing as compared to a conventional nanoparticulate composition or nanoemulsion. hi one embodiment, an improved pK profile shows a faster onset of activity and/or greater quantity of drag absorbed (i.e., greater bioavailability) than conventional nanoparticulate compositions 30 and nanoemulsions. In another embodiment, an improved pK profile allows a more effective and/or faster titration of the subject to therapeutic plasma levels. 28 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013
The present invention contemplates certain embodiments of uniform microfluidized nanoemulsions comprising an improved pharmacokinetic profile as reflected by time-to-maximum-concentration (T™*), maximum-concentration (Cmax), and/or area-under-curve (AUC) profiles. 5 In one embodiment, an administered dose of a pharmaceutical, nutraceutical, or cosmeceutical incorporated into a uniform microfluidized nanoemulsion comprises ® Tmax less than that of a conventional nanoparticulate composition and/or nanoemulsion, administered at the same dosage. Preferably the Tmax is less than about 99%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than 10 about 50%, less than about 40%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, or less than about 10% of the Tmax of a conventional nanoparticulate composition and/or nanoemulsion, administered at the same dosage.
In another embodiment, an administered dose of a pharmaceutical, nutraceutical, or cosmeceutical incorporated into a uniform microfluidized nanoemulsion comprises, a 15 Cmax greater than that of a conventional nanoparticulate composition and/or nanoemulsion, administered at the same dosage. Preferably, the Cmax is greater than about 5%, greater than about 10%, greater than about 15%, greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, 20 greater than about 100%, greater than about 110%, greater than about 120%, greater than about 130%, greater than about 140%, or greater than about 150% than the Cmax of a conventional nanoparticulate composition and/or nanoemulsion, administered at the same dosage.
In one embodiment, an administered dose of a pharmaceutical, nutraceutical, or 25 cosmeceutical incorporated into a uniform microfluidized nanoemulsion comprises an AUC greater than that of a conventional nanoparticulate composition and/or nanoemulsion, administered at the same dosage. Preferably, the AUC is greater than about 5%, greater than about 10%, greater than about 15%, greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than 30 about 60%, greater than about 70%, greater than about 80%, greater than about 90%, greater than about 100%, greater than about 110%, greater than about 120%, greater than 29 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 about 130%, greater than about 140%, or greater than about 150% than the AUC of a conventional nanoparticulate composition and/or nanoemulsion, administered at the same dosage. ΙΠ. Sterile Nanoemulsions 5 The present invention contemplates a method of making a nanoemulsion having anti-bacterial properties, hi one embodiment, the method comprises a step exposing a premix to a continuous turbulent flow at high pressure. In one embodiment, the antibacterial nanoemulsion is prepared by microfluidization. In one embodiment, the exposing comprises approximately thirty (30) seconds. In another embodiment, the 10 exposing comprises a pressure of at least 25,000 PSI. In another embodiment, the anti bacterial nanoemulsion comprises soy protein.
For example, a powdered soy protein preparation was added to water thus creating a suspension. Then, a first aliquot of the suspension was added to a first ' container (i.e., for example, a cell culture falcon flask) that served as a control. A second 15 aliquot of the suspension was microfluidized (supra) to create a nanoemulsion. The preparation was microfluidized in accordance with Example 5. The microfluidized nanoemulsion was then added to a second container. Both containers were refrigerated immediately and observed over the next several days. The control suspensions agglomerated and grew bacteria. See Figures 15A and 15B. In contrast, the 20 microfluidized nanoemulsion containing the soy protein did not agglomerate or grow bacteria. See Figures 15C and 15D.
Although it is not necessary to understand the mechanism of an invention, it is believed that the microfluidization sterilized the bacteria. It is further believed that the microfluidization shear stress resulted in a bacterial cell lysis thereby preventing further 25 bacterial growth. Consequently, it is believed that microfluidization, as contemplated herein, produces a microbiologically sterile composition.
In one embodiment, the present invention contemplates a nanoemulsion comprising an oxidizing environment produced by a method comprising a continuous turbulent flow at a high pressure. In one embodiment, the nanoemulsion comprises a 30 uniform microfluidized nanoemulsion. In one embodiment, the oxidizing environment prevents bacterial growth. In another embodiment, the oxidizing environment is 30 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 bacteriocidal. In another embodiment, the oxidizing environment provides a sterile nanoemulsion.
An oxidizing nanoemulsion environment may result from an increased surface to volume ratio. In one embodiment, the present invention also contemplates a method to 5 avoid the generation of an oxidizing environment by microfluidizing in the presence of an antioxidant. In one embodiment, the antioxidant reduces the presence of reactive oxygen species (ROS) in the microfluidized nanoemulsion. In another embodiment, the
Formulation Sample 1 Sample 2 Sample 3 Mean Plasma (unoxidized control) 4.0 2.8 3.3 3.Φ Plasma + FeCl3 (oxidized control) 12.4 16.0 13.1 13.9 1.5g DHA with 200ml milk (microfluidized) 44.0 42.6 45.8 44.1 1.75gDHA, lOOOmgVitE and 800mg Vit C with 200ml milk (not microfluidized) 12.8 19.2 20.1 17.4 1.75gDHA, lOOOmgVitE and 800mg Vit C with 200ml milk (microfluidized) 4.0 6.0 3.5 15 4.5 1.75g DHA and 800mg Vit C with 200ml milk (microfluidized) 17.5 17.8 20.8 18.7 1.75g DHA and lOOOmgVitE with 200ml milk (microfluidized) 9.8 16.7 11.4 12.6 subject. antioxid ants are encapsul ated by the nanopart icles for subsequ ent release to the 20 The ROS load within any nanoemulsion preparation can be quantitatively determined by measuring indicators of an oxidizing environment. Malondialdehyde (MDA), is a known indicator of an oxidizing environment.
Table 1: Oxidative Stress In Nanoemulsion Formulations As Measured By 25 Malondialdehve Formation
As can be seen in Table 1 above, the process of making a microfluidized nanoemulsion increases MDA levels by approximately 13-fold. Further, the presence of 30 both vitamin C and/or vitamin E completely prevented MDA generation in microfluidized nanoemulsions thereby returning MDA to homeostatic plasma levels. 31 C:\NRPortbI\DCC\SCG\4903776_ I.DOC-5/02/20 ] 3 2013200590 05 Feb 2013
The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general 5 knowledge in the field of endeavour to which this specification relates.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or 10 steps. 31a WO 2008/010788 PCT/US2006/026918 2013200590 05 Feb 2013
Experimental The following examples are specific embodiments as contemplated by the present invention and are not intended to be limiting. 5 Example 1: Stable Formulation of Plant Sterol Microfluidized Nanoemulsions This example presents one plant sterol embodiment of a microfluidized nanoemulsion. The step-wise procedure is as follows: 10 1. Heat 4g of soybean oil 2. Add 5g soy lecithin, stir and heat to 90°C 3. Add lg plant sterol, stir and heat 10 mins 4. Add 250mg polysorbate 80. 5. Heat 240mL de-ionized water to 70°C 6. Add step 4 mixture to step 5 mixture, keep stir bar and heat on for 30 mins 7. Homogenize step 6 mixture for 2-4 mins 8. Stir formulation for 10 mins on hot plate 9. Microfluidize using a M-l 10EH unit once at 25,000 PSI 10. Do particle diameter analysis using a Malvem Nano S instrument 20 The mean particle diameter (i.e., Peak 1/Peak 2) for these microfluidized plant sterol nanoemulsions was 39 nm. See Figure 1. The average particle diameter data for the plant sterol microfluidized nanoemulsion is shown in Table 2 below.
Table 2: Microfluidized Plant Sterol Nanoemulsion Diam. (nm) % Intensity Width (nm) Peak Ï: 54.16 85.86 14.36 Peak 2: 15.55 14.14 2.521 Peak 3: 0 0 0 25 Z-Average: 38.91; PDI: 0.228; Intercept: 0.9764. 32 PCT/US2006/026918 WO 2008/010788
After three months the particle diameter was again determined. The mean particle diameter (i.e., Peak 1) for this microfluidized plant sterol nanoemulsion was 64.4 nm.
See Figure 1 A. The average particle diameter data for the three month plant sterol nanoemulsion is shown in Table 3 below.
Table 3: Three Month Storage: Microfluidized Plant Sterol Nanoemulsion
Diam. (nm) % Intensity Width (nm) Peak 1: 74.8 100 120.8 Peak 2: 0 0 0 Peak 3: 0 0 0 Z-Average: 64/ ; PDI: 0.196; Intercept: 0 .969.
Example 2: Stable Formulation of Cod Liver Oil Microfluidized Nanoemulsions
This example presents one cod liver oil embodiment of a microfluidized
I nanoemulsion that has a stable particle diameter for at least four months. The step-wise procedure is as follows: 1. Heat 5g of soybean oil (65°C)
2. Add 5g cod liver oil, stir and heat to 80°C 3. Add 6g polysorbate 80, stir and heat 20 mins 4. Add 200mL de-ionized water, stir and heat 30 mins
5. Microfluidize using a Μ-110ΕΗ unit once at 25,000 PSI 6. Do particle diameter analysis using a Malvern Nano S instrument
The mean particle diameter (i.e., Peak 1/Peak 2) for this cod liver oil microfluidized nanoemulsion was 58 nm. Before microfluidization, the mean particle diameter of the cod liver oil suspension was 2,842 nm. This represents a 50-fold reduction with a single pass through the microfluidizer. Four months after the microfluidization process, the particle diameter was again determined and found not to have changed. See Figure 2. The average particle diameter data from the four-month microfluidized sample is presented in Table 4. 33 WO 2008/010788 PCT/US2006/026918 2013200590 05 Feb 2013
Table 4: Microfluidized Cod Liver Oil Nanoemulsion Four Months After Preparation Diam. (nm) % Intensity Width(nm) Peak 1: 63.92 82.22 15.62 * Peak 2: 18.51 17.78 2.771 Peak 3: 0 0 0 Z-Average: 45.15; PDI: 0.247; Intercept: 0.9707. 5 Example 3: Stable Formulation of Tocopherol Microfluidized Nanoemulsions This example presents one tocopherol embodiment of a microfluidized nanoemulsion that maintains particle diameter for at least five months. The step-wise procedure is as follows: 10 1. Heat 13.5g of soybean oil 2. Add 2g tocopherol, stir and heat to 90°C 3. Heat 2g polysorbate 80 in lOOmL de-ionized water, heat to 75°C 4. Add step 3 mixture to step 2 mixture 5. Heat 300mL di-ionized water and 6g polysorbate 80, heat till 70°C 6. Add step 4 mixture to step 5 mixture, keep stir bar and heat on 7. Homogenize step 6 mixture for 2-4 mins 8. Stir formulation for 3-5 mins on hot plate 9. Microfluidize using a Μ-110ΕΗ unit once at 25,000 PSI 10. Do particle diameter analysis using a Malvern Nano S instrument 20
The mean particle diameter for the tocopherol microfluidized nanoemulsion was 64 nm. Before microfluidization, the mean particle diameter for the tocopherol suspension was 1,362 nm. This represents a 21-fold reduction a single pass through the microfluidizer. Five months after the microfluidization process, the particle diameter was 25 again determined and found not to have changed. See Figure 3. The average particle diameter data from the five-month microfluidized sample is presented in Table 5. 34 WO 2008/010788 PCT/US2006/026918 2013200590 05 Feb 2013
Table 5: Microfluidized Tocopherol Nanoemulsion Five Months After Preparation Diam. (nm) % Intensity Width (nm) Peak 1 88.06 77.84 19.99 Peak 2 26.46 22.16 3.651 Peak 3 0 0 0 Z-Average: 58.07; PDI: 0.234; Intercept: 0.9697
Example 4: Formulation of Lutein and Zeaxanthin Microfluidized Nanoemulsions 5 This example presents one lutein/zeaxanthin embodiment of a microfluidized nanoemulsion. The step-wise procedure is as follows: 10 15 1. Heat 5g of soybean oil 2. Add 2g of lecithin 3. Heat and stir, 10 mins 4. Add 125mg of lutein and 125mg of zeaxanthin 5. Heat and stir, 10 mins 6. Heat 240ml de-ionized water, 50°C 7. Add heated water to mixture 8. Stir and heat, till it is a solution 9. Microfluidize using a Μ-110ΕΗ unit once at 25,000 PSI 10. Do particle diameter analysis using a Malvern Nano S instrument
The mean particle diameter (i.e., Peak 1/Peak 2) for the lutein and zeaxanthin 20 microfluidized nanoemulsion was 62 nm. See Figure 4. The average particle diameter data for the sample is shown in Table 6. 25 35 WO 2008/010788 PCT/US2006/026918 2013200590 05 Feb 2013
Table 6: Microfluidized Lutein/Zeaxanthin Nanoemulsion Diam. (nm) % Intensity Width (nm) Peak 1 89.45 83.96 21.1 Peak 2 22.81 16.04 2.968 Peak 3 0 0 0 Z-Average: 62.26 PDI: 0.245 Intercept: 0.976
Example 5: Formulation of Sov Protein Microfluidized Nanoemulsion 5 This example presents one soy protein embodiment of a microfluidized nanoemulsion. The step-wise procedure is as follows: 10 15 1. Heat 5g soybean oil 2. Add 5g liquid lecithin 3. Heat and stir 10 mins, 70°C 4. Heat 240mL de-ionized water, 65°C 5. Add heated water to mixture 6. Add 9g soy protein, stir and heat lOmin 7. Add 9g soy protein 8. Stir and heat 20 min, 70°C 9. Homogenize 1 min 10. Microfluidize using a M-l 10EH unit ten times at 25,000 PSI 11. Do particle diameter analysis using a Malvern Nano S instrument 20 The mean particle diameter (i.e., Peak 1/Peak 2) for the vanilla soy protein (Central Soya) microfluidized nanoemulsion was 55 nm. See Figure 5. The average particle diameter data for the sample is shown in Table 7. 25 36 PCT/US2006/026918
Table 7: Microfluidized Sov Protein Nanoemulsion i Diam. (nm) % Intensity Width (nm) Peak 1 55.15 80.32 16.45 Peak 2 290.8 19.68 82.82 Peak 3 0 0 0 Z-Average: 54.97; PDI: 0.283; Intercept: 0.9 819 WO 2008/010788 2013200590 05 Feb 2013
Example 6: Formulation of Whev Protein Microfluidized Nanoemulsion 5 This example presents one whey protein embodiment of a microfluidized nanoemulsion. The step-wise procedure is as follows: 1. Heat 5g soybean oil 2. Add 5g soy lecithin 10 3. Add 250mg polysorbate 80
4. Heat and stir 10 mins, 70°C
5. Heat 240mL de-ionized water, 65°C 6. Add heated water to mixture 7. Add 1 Og whey protein 15 8. Stir and heat 10 min 9. Homogenize 1 min
10. Microfluidize using a M-l 10EH unit once at 25,000 PSI 11. Do particle diameter analysis Malvern Nano S instrument 20 The mean particle diameter (i.e., Peak 1/Peak 2) for the whey protein microfluidized nanoemulsion was 108 nm. See Figure 6. The average particle diameter data for the sample is shown in Table 8. 25 37 PCT/US2006/026918
Table 8: Microfluidized Whev Protein Nanoemulsion
Diam. (nm) % Intensity Width (nm) Peak 1 127.7 91.3 38.09 Peak 2 23.72 6.161 2.764 Peak 3 5027 2.536 593 Z-Average: 108.2 PDI: 0.263 Intercept: 0.948 WO 2008/010788 2013200590 05 Feb 2013
Example 7: Formulation of Orange Juice. Plant Sterol and Lutein Microfluidized 5 Nanoemulsion
This example presents one orange juice/plant sterol/lutein embodiment of a microfluidized nanoemulsion. The step-wise procedure is as follows: 10 1. Heat soybean oil, 80°C 2. Add 1.5g plant sterol 3. Stir and heat, 5 min 4. Add 5g polysorbate 80 5. Add 70mg Lutein 15 6. Stir and heat, 10 min 7. Add 240mL orange juice (Tropicana®) 8. Stir and heat, 1 hour 9. Microfluidize using a M-110ΕΗ unit twice at 25,000 PSI 10. Do particle diameter analysis using a Malvern Nano S instrument 20
The mean particle diameter (i.e., Peak 1/Peak 2) for the orange juice/plant sterol/lutein microfluidized nanoemulsion was 46 nm. See Figure 7. The average particle diameter data for the sample is shown in Table 9. 25 38 WO 2008/010788 PCT/US2006/026918 2013200590 05 Feb 2013
Table 9: Microfluidized Orange Juice/Plant Sterol/Lutein Nanoemulsion , Diam. (nm) % Intensity Width (nm) Peak 1 61.55 81.57 15.32 Peak 2 17.13 16.1 2.433 Peak 3 5143 2.329 509.4 Z-Average: 46.41; PDI: 0.322; Intercept: 0.9609
Example 8: Stable Formulation of DHA Fish Qil/Water Microfluidized Nanoemulsion 5 This example presents one DHA fish oil/water embodiment of a microfluidized nanoemulsions that maintains particle diameter for at least two months. The step-wise procedure is as follows: 10 1. Heat 6.4g DHA fish oil 2. Add 6g soy lecithin 3. Add 250mg polysorbate 80 4. Heat 240mL de-ionized water, 75°C 5. Add heated water to mixture 6. Stir and heat, 20 mins 7. Homogenize 2 mins 8. Stir and heat, 10 mins 9. Microfluidize using a M-l 10ΕΗ unit once at 25,000 PSI 10. Do particle diameter analysis using a Malvern Nano S instrument. 20 The mean particle diameter (i.e., Peak 1) for the DHA fish oil/water microfluidized nanoemulsion was 73 nm. Two months after the miciofluidization process, the particle diameter was again determined and found not to have changed. See Figure 8. The average particle diameter data from the two-month microfluidized sample is presented in Table 10. 25 39 WO 2008/010788 PCT/US2006/026918 2013200590 05 Feb 2013
Table 10: Stable Microfluidized DHA Fish Oil/Water Nanoemulsion Diam. (nm) % Intensity Width (nm) Peak 1 81.73 100 20.38 Peak 2 0 0 0 Peak 3 0 0 0 Z-Average: 72.58; PDI: 0.205; Intercept: 0.9636.
Example 9: Stable Formulation of DHA Fish Oil/Milk Microfluidized Nanoemulsion 5 This example presents one DNA fish oil/milk embodiment without any added emulsifiers that maintains particle diameter for at least three (3) weeks. The step-wise procedure is as follows: 10 1. Heat 1.5g DHA fish oil, 50°C 2. Heat 200mL whole milk, 50°C 3. Mix the two together 4. Stir and heat, 10 mins 5. Microfluidize using a Μ-110ΕΗ unit once at 25,000 PSI 6. Do particle diameter analysis using a Malvern Nano S instrument 15
The mean particle diameter (i.e., Peak 1) for the DHA fish oil/milk microfluidized nanoemulsion 93 nm. This nano-emulsion preparation was made without any added emulsifiers. Three weeks after the microfluidization process, the fish oil was still in solution and the particle diameter was again determined and found not to have changed. 20 See Figure 9. The average particle diameter data from the three-week microfluidized sample is presented in Table 11. 25 40 WO 2008/010788 PCT/US2006/026918 2013200590 05 Feb 2013
Tahle 11: Stable Microfluidized DNA Fish Oil/Milk Nanoemulsion Diam. (nm) % Intensity Width (nm) Peak 1 106.9 100 32.84 Peak 2 0 0 0 Peak 3 0 0 0 Z-Average: 93.11; PDI: 0.178; Intercept: 0.9341
Example 10: Temperature Stability Of Microfluidized Nanoemulsions 5 This example presents the stability of microfluidized nanoemulsions following exposure to either heat or cold. The formulation used in this experiment comprised DHA Fish Oil milk/tocopherol. 10 15 1. Dissolved lg of vitamin C in 25mL of di-ionized water 2. Added 200mL of whole milk to step 1 3. Took 1.7g DHA fish oil and added 800mg of delta tocopherol 4. Added steps 1 and 2 to step 3 5. Stir and heat lOmins, 50°C 6. Microfluidize using a M-l 10ΕΗ unit once at 25,000 PSI 7. Do particle diameter analysis using a Malvern Nano S instrument
The mean particle diameter (i.e., Peak 1) for the DHA fish oil/milk/tocopherol microfluidized nanoemulsion was 87 nm. See Figure 10. This nano-emulsion preparation was made without any added emulsifiers. The average particle diameter data for the 20 original nanoemulsion is presented in Table 12.
Table 12: Microfluidized DNA Fish Oil/Milk/Tocopherol Original Nanoemulsion Diam. (nm) % Intensity Width (nm) Peak 1 91.84 97.86 23.95 Peak 2 5179 2.144 485.1 Peak 3 0 0 0 Z-Average: 87.09; PDI: 0.216; Intercept: 0.9339 41 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013
This original microfluidized nanoemulsion was pasteurized at 75°C for 30 seconds. Twenty-four hours later, the oil was still in solution and the particle diameter was stable as compared to the original nanoemulsion. See Figure 11. The average 5 particle diameter data for the pasteurized microfluidized nanoemulsion is presented in
Table 13.
Table 13: Microfluidized DHA Fish Oil/Milk/Toconherol Pasteurized Nanoemulsion
Diam. (run) % Intensity Width (nm) Peak 1 108.3 82.49 28.06 Peak 2 45.16 17.51 8.109 Peak 3 0 0 0 Z-Average: 87.18; P DI: 0.198; Intercept: 0.9281
The original microfluidized nanoemulsion was freeze-thaw tested at - 4°C for 24 hours. Twenty-four hours later, the oil was still in solution and the particle diameter was stable as compared to the original nanoemulsion. See Figure 12. The average particle diameter data for the freeze-thaw microfluidized nanoemulsion is presented in Table 14. 15
Table 14: Microfluidized DHA Fish Oil/Milk/Tocopherol Freeze-Thaw Nanoemulsion
Diam. (nm) % Intensity Width (nm) Peak 1 99.72 100 39.07 Peak 2 0 0 0 Z-Average: 87.58; PDI: 0.198
Example 11: Improved Bioavailabilitv Of Dietary Lvcooene 20 This example demonstrates an improved bioavailability of lycopene when fed as a uniform microfluidized nanoemulsion versus mixed into a standard diet formulation.
The lycopene microfluidized nanoemulsion was prepared in a step-wise manner as follows: 1. Heat 5g of soybean oil 42 WO 2008/010788 2013200590 05 Feb 2013 5 PCT/US2006/026918 2. Add 2g of lecithin 3. Heat and stir, 10 mins 4. Add 125mg of lycopene 5. Heat and stir, 10 mins
6. Heat 240ml de-ionized water (or grape juice); 50°C 7. Add heated water (or grape juice) to mixture 8. Stir and heat, till it is a solution
9. Microfluidize using a Μ-110ΕΗ unit once at 25,000 PSI 10. Do particle diameter analysis using a Malvern Nano S instrument
The mean particle diameter for the lycopene microfluidized nanoemulsion was 74 nm.
Bioavailability In Gerbihs 15 The microfluidized nanoemulsion was incorporated into a chow-based diet and fed to gerbils over a 4 week period. A control group was fed a lycopene in oil-enriched chow-based diet. At the end of 4 weeks, blood was collected, plasma harvested and plasma lycopene levels were determined by HPLC in both gerbil groups.
Figure 13 demonstrates that control gerbils did not demonstrate detectable plasma 20 lycopene levels. The gerbils fed a chow comprising a microfluidized lycopene nanoemulsion, however, demonstrated elevated plasma lycopene levels. See Figure 14.
Bioavailability In Humans A microfluidized lycopene nanoemulsion was then prepared with grape juice 25 instead of water and orally administered to two (2) human subjects over a 4 day period (125 mg/serving, 2 servings per day). This administration raised plasma lycopene levels by approximately 38% (data not shown). 30 43 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013
Example 12: Improved Efficacy Of Microfluidized Nanoemulsions This example presenting data showing that microfluidized nanoemulsions provide improved efficacy over that seen in traditional nanoemulsions. Specifically, this example compares the ability of three plant sterol formulations to reduce plasma low density lipoprotein cholesterol (LDL-C) levels in hypercholesterolemic hamsters. A microfluidized mixed plant sterol (60% sitosterol) nanoemulsion was prepared in a step-wise manner as follows: 1. Heat 5g soybean oil. 2. Add 5g soy lecithin, stir and heat 15 mins. 3. Repeat Step 2. 4. Add 15g soybean oil, stir and heat 10 mins. 5. Add 4g plant sterol, stir and heat 10 mins. 6. Repeat Step 4 four (4) times. 7. Add lg polysorbate 80, stir and heat 10 mins. 8. Heat 200ml MinuteMaid Heartwise® orange juice (75°C). 10. Heat 1800 ml MinuteMaid Heartwise® orange juice (70°C). 11. Add Step 8 to Step 7. Stir and heat 20 min (80°C). 12. Add to Step 10. 13. Add lg polysorbate 80, stir and heat 20 min (80°C). 14. Homogenize for 2-4 min. 15. Stir homogenate on hot plate for 10 min. 16. Microfluidize using a M-l 10EH unit at 25,000 PSI. 17. Do particle analysis using a Malvern Nano S instrument. 25 The mean particle diameter for the microfluidized plant sterol nanoemulsion was 41.95 nm. See Figure 16.
Forty (40) hamsters were divided into four (4) groups of ten (10) each. Group 1 was fed a control hypercholesterolemic diet (HCD); Group 2 was fed 30 mg/d of crystalline plant sterol; Group 3 was fed 20 mg/d of MinuteMaid Heartwise® micronized 30 plant sterol (Cargill); Group 4 was fed 10 mg/d of the microfluidized plant sterol
nanoemulsion. After four (4) weeks, blood samples were analyzed for plasma LDL-C 44 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 levels. The microfluidized plant sterol nanoemulsion was twice as effective as the MinuteMaid Heartwise® micronized diet, and three times as effective as the crystalline plant sterol diet. See Figure 17.
The data show that the improved bioavailability shown in Example 11 results in 5 improved clinical therapy when compared to micron-sized or crystalline plant sterol diets.
Example 13: Cholesterol Nanoemulsions: Insoluble vs Soluble Dispersion Media
This example presents data demonstrating that uniform microfluidized nanoemulsion compositions depend upon a compound having substantial solubility in the 10 liquid dispersion medium. This example compares the microfluidizing technique described in US Pat. No. 5,510,118 to one embodiment as contemplated by the present invention. The absorbable lipid cholesterol was chosen as the test compound.
Group I represents the ‘118 premix and was prepared by dispersing cholesterol (2 gms), water (100 mis) and Tween® 80 (0.2 gms), where cholesterol is insoluble (i.e., 15 below at least 30 mg/ml) in the liquid dispersion medium (water). Thereafter, this cholesterol/water/Tween® 80 solution was microfluidized using a M-100EH unit. Multiple passes (10-15) through the microfluidizer were performed at PSPs ranging between 4,000 - 20,000 but were terminated because the generated heat exceeded 70° C (much higher than the recommended 30-40° C in the ‘ 118 patent. After the 10 microfluidization it was observed that much of the cholesterol had precipitated. After twenty-four hours, the preparation of the Group I nanoemulsion contained only 0.44 gms (i.e., 22%) of the original cholesterol weight.
Group II represents one embodiment of the present invention and was prepared by dispersing cholesterol (2 gms) in heated soybean oil (10 gms), soy lecithin (5 gms), and 25 Tween® 80 (0.2 gms) where cholesterol is substantially soluble (i.e., above at least 30 mg/ml) in the dispersion medium (oil). Thereafter, this cholesterol/oil/lecithin/Tween® 80 was added to 100 ml of heated water and microfluidized using a single 30 second pass at 25,000 PSI using a M-100EH unit. After the microfluidization cholesterol precipitation was not noticeably evident. After twenty-four hours, the preparation of the 30 Group Π nanoemulsion contained 1.66 gm (i.e., 83%) of the original cholesterol weight. 45 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013
The data show that the particle diameter distributions from both Group I and Group Π premix preparations are practically identical. See Figure 18A and Figure 18B, respectively. Specifically, a single peak ranging from 700 -1000 nm having a mean particle diameter of approximately 900 nm is observed for both preparations. See Tables 5 15 and 16.
Table 15: Cholesterol/Tween® 80/Water Premix Particle diameter: Group I
Diam. (nm) % Intensity Width (nm) Peak 1 942.5 100 38.9 Z-Average: 1982; PDI: 0.210; Intercept: 0.6797 10
Table 16: Cholesterol/Oil/Lecithin/Tween® 80/Water Premix Particle diameter: Group II
Diam. (nm) % Intensity Width (nm) Peak 1 897.9 100 64.8 Z-Average: 1328; PDI: 0.427; Intercept: 0.6989
Following microfluidization, however, the particle diameter distributions are vastly different between Group I and Group II. See Figure 19A and Figure 19B, 15 respectively. Group I shows two vastly disparate and distinct peaks. See Table 17. Group II, however, shows a single peak representing one embodiment of a uniform microfluidized nanoemulsion. See Table 18.
Table 17: Microfluidized Cholesterol/Tween® 80/Water Nanoemulsion
Diam. (nm) % Intensity Width (nm) Peak 1 578.2 67.6 120.8 Peak 2 96.7 32.3 14.9 Z-Average: 246.5; PDI: 0.789; Intercept: 0.76 37 46 PCT/US2006/026918
Table 18: Microfluidized Cholesterol/Qil/Lecithin/Tween® 80/Water Nanoemulsion
Diam. (nm) % Intensity Width (nm) Peak 1 101.3 100 25.1 Z-Average: 86.8; PDI: 0.240; Intercept: 0.9455 WO 2008/010788 2013200590 05 Feb 2013
The data above demonstrate that some embodiments of the present invention 5 contemplate improvements over the art in creating uniform microfluidized nanoemulsions. In particular, it is now clear that the Bosch et al (‘ 118 patent), and the Cooper et al. portfolio (‘758, ‘038, and ‘202 application publications) do not teach a microfluidization process that creates a uniform particle diameter distribution. 10 Example 14: Nanoparticulate Compositions vs Uniform Microfluidized Nanoemulsions This example describes a demonstration that will show that a milled nanoparticle composition (for example, one made according to USAppln Publ No. 2004/0033202 to Cooper et al.) does not create a uniform particle diameter distribution as does a microfluidized nanoemulsion as contemplated by one embodiment of the present 15 invention. An absorbable phytosterol will be chosen as the test compound.
Group I represents the ‘202 premix that will be prepared by dispersing 5% (w/w) phytosterol/water solution with 1% (w/w) Tween® 80, where the phytocholesterol is insoluble (i.e., below at least 30 mg/ml) in the liquid dispersion medium (water). Thereafter, this phytosterol/water/Tween® 80 solution will be milled at 10°C for 1.5 to 2 20 hours in a DYNO®-Mill KDL (Willy A Bachofen AG, Machinefabrik, Basel,
Switzerland) using a 500 pm milling media (i.e., grinding beads) of type Polymill® 500. After the milling it will be observed that much of the phytocholesterol has precipitated. After at least twenty-four hours, the preparation of the Group I nanoparticulate will contain less than Vz of the original phytosterol weight. 25 Group Π represents one embodiment of the present invention and will be prepared by dispersing 5% (w/w) phytosterol/ heated soybean oil solution, soy lecithin, with 1% Tween® 80, where the phytosterol is substantially soluble (i.e., above at least 30 mg/ml) in the liquid dispersion medium (oil). Thereafter, this phytosterol/oil/lecithin/Tween® 80 premix is added to 100 ml heated water and microfluidized using a single 30 second pass 47 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013 at 25,000 PSI using a M-100EH unit. After the microfluidization phytosterol precipitation will not be noticeably evident. After twenty-four hours, the preparation of the Group Π nanoemulsion will contain greater than 3/4 of the original phytosterol weight. 5 The data will show that the particle diameter distributions from both Group I and
Group II premix preparations are practically identical. For example, a single peak ranging from 700 -1000 nm having a mean particle diameter of approximately 900 nm might be observed for both preparations. See Tables 19 and 20.
10 Table 19: Phvtosterol/Tween 80/Water Premix Particle diameter: Group I
Diam. (nm) % Intensity Width (nm) Peak 1 942.5 100 38.9 Z-Average: 1982; PDI: 0.210; Intercept: 0.6797
Table 20: Phvtosterol/Oil/Lecithin/Tween 80/Water Premix Particle diameter: Group Π
Diam. (nm) % Intensity Width (nm) Peak 1 897.9 100 64.8 Z-Average: 1328; PDI: 0.427; Intercept: 0.6989 15
Following processing however, the particle diameter distributions are expected to be vastly different between Group I and Group Π. For example, Group I will most likely show at least two vastly disparate and distinct peaks. See Table 21. Group Π, however, will have only a single peak representing one embodiment of a uniform microfluidized 20 nanoemulsion. See Table 22.
Table 21: Microfluidized Cholesterol/Tween 80/Water Nanoemulsion: Group I
Diam. (nm) % Intensity Width (nm) Peak 1 578.2 67.6 120.8 Peak 2 96.7 32.3 14.9 Z-Average: 246,5; PDI: 0.789; Intercept: 0.76 37 48 PCT/US2006/026918
Table 22: Microfluidized Cholesterol/Oil/Lecithin/Tween 80/Water Nanoemulsion: Group Π
Diam. (nm) % Intensity Width (nm) Peak 1 101.3 100 25.1 Z-Average: 86.8; PDI: 0.240; Intercept: 0.9455 WO 2008/010788 2013200590 05 Feb 2013
The data above demonstrate that nanoparticulate composition are not able to 5 create uniform particle diameter distributions as contemplated by some embodiments of the nanoemulsions contemplated herein. In particular, it is now clear that the Cooper et al. portfolio (‘758, ‘038, and ‘202 application publications) do not teach a milling process that creates a uniform particle diameter distribution. 10 Example 15: Improved Bioavailability Over Conventional Nanoparticulate Compositions This example will provide data showing that a uniform microfluidized nanoemulsion as contemplated by one embodiment of the present invention has improved plant sterol bioavailability and/or efficacy than a conventional nanoparticulate composition. 15 A standard curve will be constructed by gavaging thirty (30) hamsters with 1 pCi 3H-cholesterol. Plasma cholesterol levels are then determined at Day 1, Day 2, Day 4, and Day 7. These data are used to calculate bioavailability of 3H-cholesterol during the 7 Day period as area-under-the-curve (AUC).
After plasma radioactivity levels have returned to background levels (i.e., 20 approximately 7.5 cholesterol metabolic half-lives), the experiment will be repeated using the following treatment groups (n =10).
Group I: Standard diet mixed with a plant sterol.
Group II: Standard diet mixed with a uniform microfluidized plant sterol 25 nanoemulsion prepared in accordance with Example 1.
Group ΙΠ: Standard diet mixed with a conventional lycopene nanoparticulate composition prepared in accordance with conventional milling grinder techniques as described in the ‘202 Cooper et al. application. 49 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013
The AUC measurement will determine the ability of each preparation to reduce the absorption of ^-cholesterol into the bloodstream which is proportional to die bioavailability and/or efficacy of each preparation. 5 A greater bioavailability and/or efficacy of a plant sterol when administered as a uniform micro fluidized nanoemulsion will be seen because: i) the average particle diameter of the uniform microfluidized nanoemulsion is smaller than the conventional nanoparticulate composition (i.e., for example, 300 nm v. 50 nm); ii) microfluidization produces more stable particles than either milling or homogenization; and iii) 10 microfluidization produces pH-resistant particles (i.e., stomach acid or small intestine base conditions) unlike those produced by either milling or homogenization.
Example 16: Improved Efficacy Over Conventional Nanoparticulate Compositions This example will provide data showing that a uniform microfluidized 15 nanoemulsion as contemplated by one embodiment of the present invention has improved efficacy in lowering plasma cholesterol levels that a conventional nanoparticulate composition.
The study will have duration of six (6) weeks. Briefly, seventy (70) hamsters will be fed a liquid-based hypercholesterolemic diet for a two (2) week pre-test period in 10 order to elevate and stabilize plasma cholesterol levels. Subsequently, the hamsters are divided into the seven (7) test groups (n = 10) shown below. Each group is maintained on the liquid-based hypercholesterolemic diet and: i) a nanoparticulate composition (i.e., for example, prepared as per the ‘202 Cooper et al. application); or ii) a uniform microfluidized nanoemulsion as contemplated by one embodiment of the present 25 invention, for four (4) additional weeks.
Group I: Hypercholesterolemic diet only Group Π: Hypercholesterolemic diet + 0.1% (w/w) plant sterol nanoparticulate composition. 30 Group ΠΙ: Hypercholesterolemic diet + 0.5% (w/w) plant sterol nanoparticulate composition. 50 WO 2008/010788 PCT/US2006/026918
Group IV: Hypercholesterolemic diet + 1% (w/w) plant sterol nanoparticulate composition. Group V: Hypercholesterolemic diet + 0.1% (w/w) plant sterol uniform microfluidized nanoemulsion. 5 Group VI: Hypercholesterolemic diet + 0.5% (w/w) plant sterol uniform microfluidized nanoemulsion. Group VII: Hypercholesterolemic diet + 1% (w/w) plant sterol uniform microfluidized nanoemulsion. 2013200590 05 Feb 2013 10 Blood samples are taken at 0,2,3,4,5, and 6 weeks where plasma cholesterol levels will be determined by methods known in the art. A greater efficacy of the plant sterol uniform microfluidized nanoemulsions to lower plasma cholesterol levels is seen because: i) the average particle diameter of the uniform microfluidized nanoemulsion is smaller than the conventional nanoparticulate 15 composition (i.e., for example, 300 nm v. 50 nm); ii) microfluidization produces more stable particles than either milling or homogenization; and iii) microfluidization produces ρΗ-resistant particles (i.e., stomach acid or small intestine base conditions) unlike those produced by either milling or homogenization. 20 Example 17: Microfluidization Single Pass Comparison
This example provides data showing that the Bosch technique does not produce a uniform microfluidized nanoemulsion when compared to one embodiment of the present invention under identical microfluidization techniques.
The Group I & II premixes were prepared in accordance with Example 13. Each 25 premix was subjected to one pass at 25,000 PSI in the microfluidizer. Group I (representing the Bosch formulation) shows that 85% of the particles have a mean diameter of 815 nm. See Figure 20A. Group Π (representing one embodiment of the present invention) shows that 98% of the particles have a mean diameter of 78 nm. See Figure 20B This represents a greater than ten-fold difference in average diameter. 30 Significantly, only 15% of the Bosch particles are within the 100 nm range, thereby representing a six-fold difference in particle diameter distribution in this lower range. 51 PCT/US2006/026918 WO 2008/010788 2013200590 05 Feb 2013
The average particle diameter distributions between Group I and Group Π are presented in Tables 23 & 24 below. 5 Table 23: Microfluidized Cholesterol/Tween® 80/Water Nanoemulsion: Single Pass
Diam. (nm) % Intensity Width (ran) Peak 1 815.3 84.5 117.7 Peak 2 101.8 15.54 1Ó.54 Z-Average: 651.5; PDI: 84.5; Intercept: 0.7487
Table 24: Microfluidized Cholesterol/Qil/Lecithin/Tween® 80/Water Nanoemulsion: Single Pass
Diam. (nm) % Intensity Width (ran) Peak 1 78.43 97.47 31.43 Peak 2 19.63 2.535 2.928 Z-Average: 65.98; PDI: 0.190; Intercept: 0.92 10 52
Claims (24)
- THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:1. A method, comprising: a) providing; 5 i) a premix comprising a liquid dispersion medium selected from oil-based media and aqueous media; an emulsifier selected from fatty acid monoglycerides, fatty acid diglycerides, and polysorbates; and 10 a compound that is substantially soluble in the liquid dispersion medium; and ii) a device capable of creating a continuous turbulent flow under high pressure; b) using said device to create a uniform nanoemulsion comprising a population 15 of nanoparticles, wherein, when the premix is subjected to single-pass microfluidization, the uniform nanoemulsion is generated, the nanoemulsion being uniform in that: less than 3% of the nanoparticles show a diameter distribution outside a specified range, the specified range being that the difference between the minimum diameter and 20 maximum diameter does not exceed 600 nm; and the nanoparticles in the population have diameters wherein the specified range is between approximately 10 nm and 100 nm.
- 2. The method of Claim 1, wherein said aqueous media is selected from the group 25 consisting of water, saline solution, dextrose, and short chain alcohols.
- 3. The method of claim 2, wherein the saline solution is ringers solution.
- 4. The method of Claim 1, wherein said oil-based media is selected from the group 30 consisting of saturated and unsaturated oils from vegetable and marine sources, silicone oils, and mineral oils.
- 5. The method of Claim 1, wherein said compound is selected from the group consisting of a plant sterol, cod liver oil, tocopherol, lecithin, lutein, zeaxanthin, and soy protein. 5
- 6. The method of claim 1, wherein the compound is a pharmaceutical agent.
- 7. The method of claim 1, wherein the compound is a nutraceutical agent.
- 8. The method of claim 1, wherein the compound is a cosmeceutical agent.
- 9. The method of claim 1, wherein the compound is a protein.
- 10. The method of claim 1, wherein the device is a microfluidizer. 15
- 11. The method of claim 1, wherein the difference between the minimum and maximum diameters does not exceed 300 nm, 200 nm, or 100 nm.
- 12. The method of claim 1, 20 wherein the minimum diameter is 10 nm, and wherein the maximum diameter is 110 nm; wherein the minimum diameter is 40 nm, and wherein the maximum diameter is 110 nm; or wherein the minimum diameter is 50 nm, and wherein the maximum diameter is 25 150 nm.
- 13. The method of claim 1, wherein 86% of particles within the population have an average diameter of 54 nm.
- 14. The method of claim 1, wherein 14% of particles within the population have an average diameter of 16 nm. 54
- 15. The method of claim 1, wherein 82% of particles within the population have an average diameter of 64 nm.
- 16. The method of claim 1, wherein 17% of particles within the population have an average diameter of 19 nm.
- 17. The method of claim 1, wherein 78% of particles within the population have an average diameter of 88 nm. 10
- 18. The method of claim 1, wherein 22% of particles within the population have an average diameter of 27 nm.
- 19. The method of claim 1, wherein 84% of particles within the population have an 15 average diameter of 90 nm.
- 20. The method of claim 1, wherein 16% of particles within the population have an average diameter of 23 nm.
- 21. The method of claim 1, wherein 80% of particles within the population have an average diameter of 55 nm.
- 22. The method of any one of claims 1-21, further comprising a step of formulating the nanoemulsion for transdermal administration. 25
- 23. The method of any one of claims 1-21, further comprising a step of formulating the nanoemulsion as an ointment, a cream, or a gel.
- 24. The method of claim 1, wherein the compound is soluble in the liquid dispersion 30 medium. 55
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013200590A AU2013200590B2 (en) | 2005-07-18 | 2013-02-05 | Compositions and methods for making and using nanoemulsions |
AU2016244292A AU2016244292A1 (en) | 2005-07-18 | 2016-10-13 | Compositions and methods for making and using nanoemulsions |
AU2018220054A AU2018220054B2 (en) | 2005-07-18 | 2018-08-22 | Compositions and methods for making and using nanoemulsions |
AU2020217392A AU2020217392A1 (en) | 2005-07-18 | 2020-08-12 | Compositions and Methods for Making and Using Nanoemulsions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/700,224 | 2005-07-18 | ||
AU2006346369A AU2006346369B2 (en) | 2005-07-18 | 2006-07-11 | Compositions and methods for making and using nanoemulsions |
AU2013200590A AU2013200590B2 (en) | 2005-07-18 | 2013-02-05 | Compositions and methods for making and using nanoemulsions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006346369A Division AU2006346369B2 (en) | 2005-07-18 | 2006-07-11 | Compositions and methods for making and using nanoemulsions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016244292A Division AU2016244292A1 (en) | 2005-07-18 | 2016-10-13 | Compositions and methods for making and using nanoemulsions |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2013200590A1 AU2013200590A1 (en) | 2013-02-21 |
AU2013200590B2 true AU2013200590B2 (en) | 2016-11-03 |
Family
ID=47722630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013200590A Active AU2013200590B2 (en) | 2005-07-18 | 2013-02-05 | Compositions and methods for making and using nanoemulsions |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2013200590B2 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5651991A (en) * | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
US5851402A (en) * | 1996-10-15 | 1998-12-22 | Chemoxal S.A. | Process for the purification of hydrogen peroxide |
US6265180B1 (en) * | 1998-03-30 | 2001-07-24 | Mibelle Ag Cosmetics | Nanoemulsions for delivering lipophilic substances into cells |
US20040115159A1 (en) * | 2002-03-29 | 2004-06-17 | Tadlock Charles C | Novel nanoemulsions |
US20050048088A1 (en) * | 2003-08-28 | 2005-03-03 | Fred Zulli | Compositions comprising at least two nanoemulsions |
WO2005020962A1 (en) * | 2003-08-29 | 2005-03-10 | Novagali Pharma Sa | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
EP1249232B1 (en) * | 2001-04-13 | 2006-10-11 | Pacific Corporation | Controlled release nanoparticles for percutaneous use and composition containing the same |
-
2013
- 2013-02-05 AU AU2013200590A patent/AU2013200590B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5651991A (en) * | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
US5851402A (en) * | 1996-10-15 | 1998-12-22 | Chemoxal S.A. | Process for the purification of hydrogen peroxide |
US6265180B1 (en) * | 1998-03-30 | 2001-07-24 | Mibelle Ag Cosmetics | Nanoemulsions for delivering lipophilic substances into cells |
EP1249232B1 (en) * | 2001-04-13 | 2006-10-11 | Pacific Corporation | Controlled release nanoparticles for percutaneous use and composition containing the same |
US20040115159A1 (en) * | 2002-03-29 | 2004-06-17 | Tadlock Charles C | Novel nanoemulsions |
US20050048088A1 (en) * | 2003-08-28 | 2005-03-03 | Fred Zulli | Compositions comprising at least two nanoemulsions |
WO2005020962A1 (en) * | 2003-08-29 | 2005-03-10 | Novagali Pharma Sa | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
Also Published As
Publication number | Publication date |
---|---|
AU2013200590A1 (en) | 2013-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10016364B2 (en) | Compositions and methods for making and using nanoemulsions | |
AU2019398117B2 (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof | |
TWI290052B (en) | Emulsion vehicle for poorly soluble drugs | |
Gorjian et al. | Preparation and characterization of the encapsulated myrtle extract nanoliposome and nanoniosome without using cholesterol and toxic organic solvents: A comparative study | |
WO2008101344A1 (en) | Soluble bioactive lipophilic compounds compositions | |
US11173127B2 (en) | Potato protein nanoparticles | |
AU2018220054B2 (en) | Compositions and methods for making and using nanoemulsions | |
AU2013200590B2 (en) | Compositions and methods for making and using nanoemulsions | |
US20220054414A1 (en) | Nanoemulsion Compositions Comprising Saponins for Increasing Bioavailability | |
Kaur | Nanoemulsions as delivery vehicles for food and pharmaceuticals | |
Sridhar et al. | Recent Advances on Nanoparticle Based Strategies for Improving Carotenoid Stability and Biological Activity. Antioxidants 2021, 10, 713 | |
Kharat | Design and Fabrication of Colloidal Delivery Systems to Encapsulate and Protect Curcumin: An Important Hydrophobic Nutraceutical | |
Leibtag | A Comprehensive Study on Ultrasonically Prepared Nanoemulsions: Formulation Development, Influence of Processing Parameters and Efficacy as Hydrophobic Drug Carriers | |
Bhatt et al. | Nanoemulsion through cold emulsification: An advanced cold manufacturing process for a stable and advanced drug delivery system | |
WO2023283277A1 (en) | Fermented uni-sourced nanoemulsion of nigella sativa or cannabis sativa for use in medical, cosmetic, and recreational indications with a method of its production and use | |
Giri | Letters in Applied NanoBioScience |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |